Designer Osteogenic Proteins

Wyeth Llc
Granted App No 841/DELNP/2013 Patent 330471 Pharmaceuticals

Patent information

IP India · live record
Application number
841/DELNP/2013
Filing date
28 January 2013
Status
Granted
Legal status
Inforce
Publication number
43/2014
Publication type
INA
Invention field
Pharmaceuticals
Patent number
330471
Grant date
28 January 2020
Next renewal due
17 August 2026Overdue

Abstract

The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor nucleic acids encoding the same and methods of use therefor. More preferably the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.

Applicants

1
U.S.A.
WYETH LLC Five Giralda Farms Madison NJ 07940

Inventors

8
U.S.A.
BERASI Stephen PeterPfizer Global Research & Development 87 Cambridge Park Drive Cambridge Massachusetts 02140
U.S.A.
BROWN Christopher ToddPfizer Global Research & Development 87 Cambridge Park Drive Cambridge Massachusetts 02140
U.S.A.
CAIN Michael JohnPfizer Global Research & Development 87 Cambridge Park Drive Cambridge Massachusetts 02140
France
CALABRO Valerie PerrineAvenue de Carro Residence "Le Baoutailla" Apt. 34 F 13500 Carro
U.S.A.
JUO Zong SeanPfizer Global Research & Development 87 Cambridge Park Drive Cambridge Massachusetts 02140
U.S.A.
MARTINEZ Robert Vincent PaulPfizer Global Research & Development 87 Cambridge Park Drive Cambridge MA 02140
U.S.A.
SEEHERMAN Howard JoelPfizer Global Research & Development 87 Cambridge Park Drive Cambridge Massachusetts 02140
U.S.A.
WOZNEY John MartinPfizer Global Research & Development 87 Cambridge Park Drive Cambridge Massachusetts 02140

Specification

Show full textCollapse

DESIGNER OSTEOGEN IC PROTEINS FIELD OF THE INVENTION This application relates to the field of osteogenic proteins, methods of making improved osteogenic proteins, and methods of treating patients with osteogenic proteins. BACKGROUND OF THE INVENTION The cystine knot cytokine superfamily is divided into subfamilies, which include, the transforming growth factor b (TGFP) proteins, the glycoprotein hormones, the platelet-derived growth factor-like (PDGF-like) proteins, nerve growth factors (NGF), and the differential screening-selected gene aberrative in neuroblastoma (DAN) family (e.g. , cerberus). In turn, the TGFp superfamily comprises approximately 43 members, subdivided into three subfamilies: the TGFps, the activins and the bone morphogenetic/growth differentiation factor proteins (BMP/GDF). The TGF- b superfamily members contain the canonical cystine knot topology. That is, cystine knots are the result of an unusual arrangement of six cysteine residues. The knot consists of bonds between cysteines 1-4, cysteines 2-5, and the intervening sequence forming a ring, through which the disulfide bond between cysteines 3-6 passes. The active forms of these proteins are homodimers or heterodimers. In each case the monomer topology is stabilized by the cysteine knot and additional cysteines contribute to additional intrachain bonds and/or mediate dimerization with another protein unit. See Kingsley, 1994, Genes Dev. 8:1 33-1 46; Lander et al, 2001 , Nature 409:860-921 . BMP/GDFs are the most numerous members of the TGF- b protein superfamily. The BMP/GDF subfamily includes, but is not limited to, BMP2, BMP3 (osteogenin), BMP3b (GDF-1 0), BMP4 (BMP2b), BMP5, BMP6, BMP7 (osteogenic protein-1 or OP1 ) , BMP8 (OP2), BMP8B (OP3), BMP9 (GDF2), BMP1 0 , BMP1 1 (GDF1 1) , BMP1 2 (GDF7), BMP1 3 (GDF6, CDMP2), BMP1 5 (GDF9), BMP1 6, GDF1 , GDF3, GDF5 (CDMP1 ; MP52), and GDF8 (myostatin). BMPs are sometimes referred to as Osteogenic Protein (OPs), Growth Differentiation Factors (GDFs), or Cartilage-Derived Morphogenetic Proteins (CDMPs). BMPs are also present in other animal species. Furthermore, there is some allelic variation in BMP sequences among different members of the human population. BMPs are naturally expressed as pro-proteins comprising a long pro-domain, one or more cleavage sites, and a mature domain. This pro-protein is then processed by the cellular machinery to yield a dimeric mature BMP molecule. The pro-domain is believed to aid in the correct folding and processing of BMPs. Furthermore, in some but not all BMPs, the pro-domain may noncovalently bind the mature domain and may act as a chaperone, as well as an inhibitor (e.g., Thies et al., Growth Factors 18:251 -9 (2001 )). BMP signal transduction is initiated when a BMP dimer binds two type I and two type I I serine/threonine kinase receptors. Type I receptors include, but are not limited to, ALK-1 (Activin receptor-Like Kinase 1) , ALK-2 (also called ActRIa or ActRI), ALK-3 (also called BMPRIa), and ALK-6 (also called BMPRIb). Type I I receptors include, but are not limited to, ActRlla (also called ActRII), ActRllb, and BMPRII. The human genome contains 12 members of the receptor serine/threonine kinase family, including 7 type I and 5 type I I receptors, all of which are involved in TGF- b signaling (Manning et al., Science 298: 19 12-34 (2002)), the disclosures of which are hereby incorporated by reference). Thus, there are 12 receptors and 43 superfamily members, suggesting that at least some TGF- b superfamily members bind the same receptor(s). Following BMP binding, the type I I receptors phosphorylate the type I receptors, the type I receptors phosphorylate members of the Smad family of transcription factors, and the Smads translocate to the nucleus and activate the expression of a number of genes. BMPs are among the most numerous members of TGF- b superfamily, and control a diverse set of cellular and developmental processes, such as embryonic pattern formation and tissue specification as well as promoting wound healing and repair processes in adult tissues. BMPs were initially isolated by their ability to induce bone and cartilage formation. BMP signaling is inducible upon bone fracture and related tissue injury, leading to bone regeneration and repair. BMP molecules which have altered affinity for their receptors would have improved biological activity relative to the native proteins. Such BMPs include proteins with increased in vivo activity and may provide potential improved therapeutics for, among other things, tissue regeneration, repair, and the like, by providing greater or altered activity at lower protein levels thereby providing improved protein therapeutics. SUMMARY OF THE INVENTION The invention includes a designer BMP protein comprising at least one mutation in at least one type I or type I I receptor binding domain, wherein the mutation confers altered binding to the type I or type I I BMP receptor compared with the binding to the type I or type I I receptor by a corresponding wild type BMP. In one aspect, the protein is selected from the group consisting of BMP2, BMP4, BMP5, BMP6, BMP7, BMP8 and BMP9. In another aspect, the protein comprises at least one mutation within: the type I I binding domain A; the type I I binding domain B; the type I binding domain; and any combination thereof. The invention also includes a designer osteogenic protein comprising an amino acid sequence comprising at least one mutation in at least one type I or type I I receptor binding domain, wherein the mutation confers altered binding to the type I or type I I BMP receptor compared with the binding to the type I or type I I receptor by wild type BMP2. In one aspect, the mutation is a mutation within the type I I binding domain A wherein said mutation is at least one mutation selected from the group consisting of a mutation at V33, P36, H39, and F41 with respect to the sequence of SEQ ID NO:1 . In another aspect, the is a mutation within the type I I binding domain A wherein said mutation is at least one mutation selected from the group consisting of V33I, P36K, P36R, H39A, and F41 N with respect to SEQ ID NO:1 . In yet another aspect, the mutation is a mutation within the type I I binding domain B wherein said mutation is at least one mutation selected from the group consisting of a mutation at E83, S85, M89, L92, E94, E96, K97, and V99 with respect to the sequence of SEQ ID NO: 1. In a further aspect, the mutation is a mutation within the type I I binding domain B wherein said mutation is at least one mutation selected from the group consisting of E83K, S85N, M89V, L92F, E94D, E96S, K97N , and V99I with respect to of SEQ ID NO: 1. In another aspect, the mutation is a mutation within the type I binding domain wherein said mutation is at least one mutation selected from the group consisting of a mutation at H44, P48, A52, D53, L55, S57, N68, S69, V70, an insertion of a single amino acid after N71 , S72, K73, I74, A77, and V80 with respect to the sequence of SEQ ID NO:1 . In yet another aspect, the mutation is a mutation within the type I binding domain wherein said mutation is at least one mutation selected from the group consisting of H44D, P48S, A52N, D53A, L55M, S57A, N68H, S69L, V70M, insertion of P after N71 , S72E, K73Y, I74V, A77P, and V80A with respect to the sequence of SEQ ID NO:1 . In a further aspect, the protein comprises a mutation at each of amino acids H44, P48, A52, D53, L55, S57, N68, S69, V70, insertion of a single amino acid after N71 , S72, K73, I74, A77, and V80 with respect to the sequence of SEQ ID NO:1 . In another aspect, the protein comprises a mutation at each of amino acids H44, P48, A52, D53, L55, S57, N68, S69, V70, insertion of a single amino acid after N71 , S72, K73, I74, A77, and V80 with respect to the sequence of SEQ ID NO:1 wherein the mutations are H44D, P48S, A52N, D53A, L55M, S57A, N68H, S69L, V70M, insertion of a P after N71 , S72E, K73Y, I74V, A77P, and V80A. In yet another aspect, the protein comprises a mutation at each of amino acids V33, P36, H39, S85, M89, L92, E94, E96, K97, and V99 with respect to the sequence of SEQ ID NO:1 . In another aspect, the protein comprises a mutation at each of amino acids V33, P36, H39, S85, M89, L92, E94, E96, K97, and V99 with respect to the sequence of SEQ ID NO:1 , wherein the mutations are V33I, P36K, H39A, S85N, M89, L92F, E94D, E96S, K97N, and V99I. In a further aspect, the protein comprises a mutation at each of amino acids V33, P36, H39, H44, P48, A52, D53, L55, S57, N68, S69, V70, insertion of a single amino acid after N71 , S72, K73, I74, A77, and V80, S85, M89, L92, E94, E96, K97, and V99 with respect to the sequence of SEQ ID NO:1 . In yet another aspect, the protein comprises a mutation at each of amino acids V33, P36, H39, H44, P48, A52, D53, L55, S57, N68, S69, V70, insertion of a single amino acid after N71 , S72, K73, I74, A77, and V80, S85, M89, L92, E94, E96, K97, and V99 with respect to the sequence of SEQ ID NO:1 wherein the mutations are V33I , P36K, H39A, H44D, P48S, A52N, D53A, L55M, S57A, N68H, S69L, V70M, insertion of a P after N71 , S72E, K73Y, I74V, A77P, and V80A, S85N, M89, L92F, E94D, E96S, K97N , and V99I . In yet another aspect, the protein comprises a mutation at each of amino acids V33, P36, H39, H44, P48, A52, D53, L55, S57, N68, S69, V70, insertion of a single amino acid after N71 , S72, K73, I74, A77, and V80, S85, M89, L92, E94, E96, K97, and V99 with respect to the sequence of SEQ ID NO:1 wherein the mutations are V33I , P36R, H39A, H44D, P48S, A52N, D53A, L55M, S57A, N68H, S69L, V70M, insertion of a P after N71 , S72E, K73Y, I74V, A77P, and V80A, S85N, M89, L92F, E94D, E96S, K97N , and V99I . In another aspect, the protein binds: the ALK2 receptor with a K not greater than about 2 nM; the ALK3 receptor with a K not greater than about 2 nM; the ALK6 receptor with a K not greater than about 1 nM; the ActRI IA receptor with a K not greater than about 2 nM; the ActRIIB receptor with a K not greater than about 0.5 nM; and the BMPRIIA receptor with a K not greater than about 3.5 nM. In one aspect, the protein further comprises 1, 2 , 3, 4 , 5 , 6 , 7, 8 , 9 , or 10 amino acid mutations not located within the type I or the type I I binding regions. The invention includes a designer osteogenic protein comprising the amino acid sequence of any one of SEQ ID NOs:8-73. The invention includes a designer osteogenic protein comprising the amino acid sequence of SEQ ID NO:1 2 . The invention includes a designer osteogenic protein comprising the amino acid sequence of SEQ ID NO:1 4 . The invention includes a designer osteogenic protein comprising the amino acid sequence of SEQ ID NO:36. The invention includes a designer osteogenic protein comprising the amino acid sequence of SEQ ID NO:37. The invention includes method of producing a designer BMP protein comprising at least one mutation in at least one type I or type I I receptor binding domain, wherein the mutation confers altered binding to the type I or type I I BMP receptor compared with the binding to the type I or type I I receptor by a corresponding wild type BMP. The method comprises introducing a nucleic acid encoding the protein into a host cell, culturing the cell under conditions where the protein is produced, and purifying the protein. In one aspect, the nucleic acid comprises a sequence selected from the nucleic acid sequence of any one of SEQ ID NOs:74-1 39. The invention includes a designer BMP6 protein comprising an amino acid sequence comprising at least one mutation in at least one type I or type I I receptor binding domain, wherein the mutation confers altered binding to the type I or type I I BMP receptor compared with the binding to the type I or type I I receptor by wild type BMP6. In one aspect, the mutation is a mutation within the type I I binding domain A wherein said mutation is at least one mutation selected from the group consisting of a mutation at I57, K60, G61 , A63, N65, Y66, and D68 with respect to the sequence of SEQ ID NO:4. In another aspect, the mutation is a mutation within the type I I binding domain B wherein said mutation is at least one mutation selected from the group consisting of K 108, N110 , A 111, V 114 , F 117 , D 119 , N 120, S 12 1, N122, V 123, and 1124 with respect to the sequence of SEQ ID NO:4. In yet another aspect, the mutation is a mutation within the type I binding domain wherein said mutation is at least one mutation selected from the group consisting of a mutation at S72, N76, A77, H78, M79, N80, A81 , N83, V87, T89, H92, L93, M94, N95, P96, E97, Y98, V99, and P 100 with respect to the sequence of SEQ ID NO:4. In another aspect, the mutation is a mutation at each of amino acid residues I57, K60, G61 , A63, N65, Y66, and D68 with respect to the sequence of SEQ ID NO:4. In a further aspect, the mutation is a mutation at each of amino acid residues K 108, N 110 , A 111, V 114 , F 117 , D 119 , N 120, S 12 1, N 122, V 123, and 1124 with respect to the amino acid sequence of SEQ ID NO:4. In yet another aspect, the mutation is a mutation at each of amino acid residues S72, N76, A77, H78, M79, N80, A81 , N83, V87, T89, H92, L93, M94, N95, P96, E97, Y98, V99, or P 100 with respect to the amino acid sequence of SEQ ID NO:4. In another aspect, the designer BMP6 protein comprising an amino acid sequence comprising at least one mutation in at least one type I or type I I receptor binding domain, wherein the mutation confers altered binding to the type I or type I I BMP receptor compared with the binding to the type I or type I I receptor by wild type BMP6 further comprises 1, 2 , 3 , 4 , 5 , 6, 7, 8 , 9 , or 10 amino acid mutations not located within the type I or the type I I binding domains. The invention includes an isolated nucleic acid molecule comprising a nucleotide sequence encoding an amino acid sequence selected from the group consisting of the sequence of SEQ ID NOs:8 to 73. In one aspect, the nucleic acid encodes a protein comprising an amino acid sequence selected from the group consisting of the sequence of SEQ ID NO:1 2 , SEQ ID NO:1 4 , SEQ ID NO:36 and SEQ ID NO:37.$$ The invention includes an isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:74 to 139. In one aspect, the nucleic acid comprises a nucleotide sequence selected from the group consisting of the sequence of SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:1 02, and SEQ ID NO: 103. The invention includes a method of producing the designer BMP6 protein comprising an amino acid sequence comprising at least one mutation in at least one type I or type I I receptor binding domain, wherein the mutation confers altered binding to the type I or type I I BMP receptor compared with the binding to the type I or type I I receptor by wild type BMP6. The method comprises introducing a nucleic acid encoding said protein into a host cell, culturing said cell under conditions where said protein is produced, and purifying said protein. The invention includes a method of treating a bone disease associated with bone loss in a patient in need thereof. The method comprises administering a therapeutically effective amount of a designer BMP protein comprising at least one mutation in at least one type I or type I I receptor binding domain, wherein the mutation confers altered binding to the type I or type I I BMP receptor compared with the binding to the type I or type I I receptor by a corresponding wild type BMP protein to the patient, thereby treating bone disease in the patient. The invention includes a method of treating fibrosis in a patient in need thereof. The method comprises administering a therapeutically effective amount of a designer BMP protein comprising at least one mutation in at least one type I or type I I receptor binding domain, wherein the mutation confers altered binding to the type I or type I I BMP receptor compared with the binding to the type I or type I I receptor by a corresponding wild type BMP to the patient, thereby treating fibrosis. The invention includes a method of inducing bone formation in a tissue. The method comprises contacting the tissue with a designer BMP protein comprising at least one mutation in at least one type I or type I I receptor binding domain, wherein the mutation confers altered binding to the type I or type I I BMP receptor compared with the binding to the type I or type II receptor by a corresponding wild type BMP, thereby inducing bone formation in said tissue. BRIEF DESCRIPTION OF THE DRAWINGS For the purpose of illustrating the invention, there are depicted in the drawings certain embodiments of the invention. However, the invention is not limited to the precise arrangements and instrumentalities of the embodiments depicted in the drawings. Figure 1, comprising panels A-C, is a diagram showing the alignment of various wild type and designer BMP amino acid sequences and indicating (by being within a box) the regions of these proteins potentially involved in type I and type I I receptor interactions. Figure 1A shows the amino acid sequence alignment of wild type BMP2, BMP4, BMP5, BMP6, BMP7, BMP8 and BMP9. Figure 1B shows the amino acid sequence alignment of various designer BMPs where the corresponding wild type BMP is BMP2. Figure 1C shows the amino acid sequence alignment of various designer BMP6 molecules where the corresponding wild type BMP is BMP6. Figure 2 is an illustration of a structural model showing a wild type BMP2 homodimer binding to two type I and two type I I BMP receptors. Figure 3, comprising panels A and B, is an diagram of a structural model showing the position of the histidine doorstop (H54) in human BMP2 produced in Chinese Hamster Ovary (CHO) (Figure 3A) and E. coli cells (Figure 3B). Figure 4 , comprising panels A and B, is a diagram illustrating the location of the glycan tether and potential histidine (His) doorstop. Figure 4A shows the glycan tether (N-linked glycan at N56) and histidine 54, in the non-doorstop orientation, as well as the interaction of the glycan tether with R 16 all in CHO-produced BMP2. Figure 4B shows the glycan tether (N-linked glycan at N80) and the histidine in the non-doorstop configuration at H78 in BMP6, as well as the R39 corresponding to R 16 in BMP2. The sequence alignment of BMP2 ( 11-KSSCKRHP) and BMP6 (35-KTACRKHE) showing the corresponding amino acids between BMP2 and BMP6 is shown along the top of the figure. Figure 5 , comprising panels A-D, shows various steps in the process for purification of BMPs and designer BMPs. Figure 5A shows a chromatogram showing gradient elution of BMPs using a cellufine sulfate column. Figure 5B is an image of a Coomassie stained SDS-PAGE (non-reduced on the left and reduced on the right side) gel containing samples of fractions from the cellufine sulfate column step. Figure 5C shows a chromatogram showing the profile from preparative reversed phase purification step. Figure 5D is an image of a Coomassie stained SDS-PAGE (non-reduced on the left and reduced on the right) gel of BMP containing samples of the fractions obtained by the preparative reversed phase purification step. Figure 6 , comprising panels A-D, show images of Coomassie-stained SDS-PAGE protein gels showing purified BMP2 wild type and various mutants as indicated along the top of each gel image. The gels were run under either non-reducing (Figures 6A and 6B) and reducing (Figures 6C and 6D) conditions. Figure 7 shows alkaline phosphatase assay results in C2C1 2 pre-myoblasts comparing the osteogenic activity of wild type BMP2 and BMP2/6 heterodimer to the various designer BMPs as indicated in the graph legend. Figure 8 shows the results of a C2C1 2 BMP-Response Element luciferase (BRE-luciferase) assay indicative of Smad activity showing stronger signaling by BMPE compared to BMP2 and equivalent signaling to BMP2/6. Figure 9 , comprising panels A and B, shows the ectopic bone formation mediated by various BMPs. Figure 9A is a graph showing the amount of ectopic bone (calculated as milligrams of hydroxyapatite; mg HA) as determined by mOT analysis for each limb which was implanted with the indicated BMP (BMP2, BMPE, and BMP2/6) at the dose indicated (0. 1 or 0.5 . Figure 9B is a graph showing the amount of ectopic bone (calculated as milligrams of hydroxyapatite) as determined by mOT analysis for each limb which was implanted with the indicated BMP (BMP2, BMPG, BMPA, and BMPF) at the dose indicated (0. 1 or 0.5 mg). The data presented are from 2 separate experiments. Figure 10 , comprising panels A-D, shows images of radiographs showing the results of a nonhuman primate (NHP) fibula osteotomy model at 4 and 8 weeks. Radiographs are shown of the fibulas of 7 representative NHPs that received BMPE and BMPG, respectively, at 0.5 mg/ml (250 m total BMP delivered/limb). Each NHP received WT BMP2 at the same dose in the contralateral limb. Figures 10A and 10B show the radiographs for the NHPs indicated at the top of each diagram showing the effects of BMPE compared with BMP2 wild type at 4 weeks and 8 weeks, respectively. Figures 10C and 10D show the radiographs for the NHPs indicated at the top of each diagram showing the effects of BMPG compared with BMP2 wild type at 4 weeks and 8 weeks, respectively. Figure 11 is a graph showing the bone volume of the limbs treated with BMP-E versus contralateral limbs treated with BMP-2. Figure 12 is a graph showing results of an alkaline phosphatase assay in C2C1 2 pre-myoblasts comparing the osteogenic activity of wild type BMP2 and BMP-GER, BMP-GEP, and BMP2/6 heterodimer. Figure 13 is a graph showing the amount of ectopic bone (calculated as milligrams of hydroxyapatite) as determined by mOT analysis for each limb which was implanted with the indicated BMP (BMP-2, BMP-2/6, BMP-E, BMP-GER, and BMP-6) at the dose indicated (0.05 or 0.25Mg). Figure 14 is a graph showing the amount of ectopic bone (calculated as milligrams of hydroxyapatite) as determined by mOT analysis for each limb which was implanted with the indicated BMP (BMP-2, BMP-2/6, BMP-E, BMP-GER, and BMP-6) at the dose indicated (0.05 or 0.25Mg). These are the results from an experiment separate from that shown in Figure 13 . Figure 15, comprising panels A and B, shows images of radiographs and mOT images showing the results of a non-human primate (NHP) fibula wedge osteotomy model at 5 and 10 weeks. Figure 15A shows images of 5-week radiographs obtained in a NHP fibula wedge osteotomy model. Figure 15A shows images of the fibulas of 4 representative NHPs which received BMP-GER in one limb and WT BMP-2 in the contralateral limb at 0.5 mg/ml (250 total BMP delivered/limb) at 5 weeks. Figure 15B shows uCT images of the same limbs at 10 weeks showing the large calluses of the BMP-GER treated limbs compared with the BMP2-treated contralateral limbs for each animal. Figure 16, comprising panels A-C, shows graphs illustrating the strength (Figure 16A), stiffness (Figure 16B), and callus bone volume (Figure 16C) of the BMP-GER treated limbs versus the BMP-2 treated contralateral limbs. Figure 17, comprising panels A-C, shows radiographic images of the healing over time of 3 nonhuman primate's (NHP) fibulas treated with BMP-GER at 0.5 mg/ml and BMP-2 in the contra lateral limb at 1.5mg/ml using a calcium phosphate based cement as a carrier following the wedge defect model. Figure 17A, upper panel, shows results for NHP number 1 left arm treated with 0.5 mg/ml GER as follows: panels 1 and 2 show LAT (lateral) and AP (anterior-posterior) images, respectively, at the initial time point; panels 3 and 4 show LAT and AP images, respectively, at 2 weeks; panels 5 and 6 show LAT and AP images, respectively, at 4 weeks; panels 7 and 8 show LAT and AP images, respectively, at 6 weeks; panels 9 and 10 show LAT and AP images, respectively, at 7 weeks; panels 11 and 12 show LAT and AP images, respectively, at 8 weeks; Figure 17A, lower panel, shows results for NHP number 1 right arm treated with 1.5 mg/ml BMP-2 as follows: panels 1 and 2 show LAT (lateral) and AP (anterior-posterior) images, respectively, at the initial time point; panels 3 and 4 show LAT and AP images, respectively, at 2 weeks; panels 5 and 6 show LAT and AP images, respectively, at 4 weeks; panels 7 and 8 show LAT and AP images, respectively, at 6 weeks; panels 9 and 10 show LAT and AP images, respectively, at 7 weeks; panels 11 and 12 show LAT and AP images, respectively, at 8 weeks; Figure 17B shows the radiographic the results for NHP number 2 as described for NHP # 1 in Figure 17A; and Figure 17C sets out the results for NHP number 3 as described for NHP # 1 in Figure 17A. Figure 18 is a diagram of a structural model showing representations and comparison of the crystal structures BMP-E and BMP-6 WT. The differences in the length of the glycan resolved is highlighted showing that the glycan for BMPE that is resolved is much longer than that for BMP6. This indicates that the BMPE glycan is more conformationally constrained than that of BMP6 such that more of the glycan can be rendered in this model. The histidine doorstop residues for both BMPE and BMP6 are shown in similar non-doorstop configurations. Also, the arginine glycan "tether" stabilizing the BMPE glycan is shown by dotted lines representing the interactions of the arginine with the glycan. Figure 19 is a closer view of the histidine doorstop and arginine tether of the BMPE and BMP6 comparison shown in Figure 18 . This image shows the similar conformation of the H54 histidine residue of BMPE and the equivalent histidine of BMP6 both in the non-doorstop position. The image also shows the R 16 tethering (via interactions of the BMPE glycan such that the glycan is more rigid and therefore more is rendered by the model compared to the more "floppy" and less constrained glycan of BMP6 such that less of the BMP6 glycan is visualized in this model. The diagram of this model also shows the similar positioning of asparagine N56 of BMPE showing N-linked attachment of the glycan and the equivalent and similarly positioned asparagine of BMP6. The diagram also illustrates the potential additional glycan tethering interaction of BMPE E 110 shown by dotted lines between the amino acid residue and the distal end of the glycan. The differences in the length of the glycan resolved is highlighted showing that less of the darker BMP6 glycan can be resolved compared with the lighter shaded longer glycan rendered for BMPE indicating that the BMPE glycan is more conformationally constrained and thus more is rendered upon structural analysis. Figure 20 is a graph showing the results of an alkaline phoshatase assay using C2C1 2 premyoblasts comparing the osteogenic activity of BMP-2, BMPE and BMP-6 with their Endo-H treated deglycosylated (Degly.) counterparts. Figure 2 1 is a diagram illustrating the structural model of BMPE showing the location of the glycan tether at R 16 and illustrating the stabilizing interactions between the arginine (R1 6) and glutamic acid (E1 10 corresponding to E 109 of BMP2) residues. The diagram shows that R 16 and E 110 both form multiple hydrogen bonds with the third (b-mannose) and fourth (a-mannose) glycan moieties. The diagram also shows the position of H54 potential "doorstop" and asparagine 56 (N56) which provides the N-linked attachment site of the glycan. Figure 22 is a graph showing the results of an alkaline phoshatase assay using C2C1 2 premyoblasts comparing the osteogenic activity of BMP-E, with BMP-E-NR, BMP-GER and BMP-GER-NR in the presence of increasing doses of Noggin - a natural inhibitor of BMP-2. The data demonstrate that BMP-GER-NR comprising sequences derived from activin was not inhibited by Noggin even at high concentrations but that BMP-GER was sensitive to Noggin inhibition. Thus, addition of sequences derived from activin caused BMP-GER to become Noggin resistant (NR). These results demonstrate that at least in this in vitro assay, BMP-GER and BMPE, which are Noggin sensitive, become Noggin resistant (NR) upon replacement of the C-terminal region of the protein with sequences derived from activin. Figures 23 is a graph showing the bone score as determined by immunohistochemistry (IHC) for rat ectopic implants treated with the indicated BMP at the specified dose. The data show that the bone forming activity of BMP-GER was greatly decreased when the C-terminal sequence of the molecule was replaced with a sequence derived from activin (NR). Thus, the data demonstrate that BMP-GER-NR was much less active than BMP-GER in vivo. Figures 24 is a graph showing the bone score as determined by immunohistochemistry (IHC) for rat ectopic implants treated with the indicated BMP at the specified dose. The data show that the bone forming activity of BMP-E was greatly decreased, indeed, it was completely abrogated , when the Cterminal sequence of the molecule was replaced with a sequence derived from activin (NR). DETAILED DESCRIPTION OF THE INVENTION This invention relates a "designer" bone morphogenetic protein, referred to herein as "designer BMP," "designer osteogenic protein" and "designer protein." The designer BMPs of the invention may correspond to the amino acid sequences of wild type unmodified BMP, such as, but not limited to, BMP2, BMP4, BMP5, BMP6, BMP7, BMP8, and BMP9. In particular embodiments, the designer BMPs show altered binding to a type I and/or type I I BMP receptor when compared to its corresponding wild type BMP. In further embodiments, the designer BMP may be modified to have altered half-life, immunogenicity, or any pharmacokinetic/pharmacodynamic (PK/PD) parameter when compared to its corresponding BMP. Definitions Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described herein are those well known and commonly used in the art. The methods and techniques of the present invention are generally performed according to methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. Such references include, e.g. , Sambrook and Russell, Molecular Cloning, A Laboratory Approach, Cold Spring Harbor Press, Cold Spring Harbor, NY (2001 ) , Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, NY (2002), and Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY ( 1990), which are incorporated herein by reference. Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclatures used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients. As used herein, each of the following terms has the meaning associated with it in this section. The articles "a" and "an" are used herein to refer to one or to more than one (i.e. , to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element. In this application, the use of "or" means "and/or" unless stated otherwise. Conventional notation is used herein to portray polypeptide sequences: the left-hand end of a polypeptide sequence is the amino-terminus; the right-hand end of a polypeptide sequence is the carboxyl-terminus. As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. See Immunology-A Synthesis (2nd Edition, E. S. Golub and D. R. Gren, Eds., Sinauer Associates, Sunderland, Mass. ( 1991 )), which is incorporated herein by reference. As used herein, amino acids are represented by the full name thereof, by the three letter code corresponding thereto, or by the one-letter code corresponding thereto, as indicated as follows: Full Name Three-Letter Code One-Letter Code Aspartic Acid Asp D Glutamic Acid Glu E Lysine Lys K Arginine Arg R Histidine His H Tyrosine Tyr Y Cysteine Cys C Asparagine Asn N Glutamine Gin Q Serine Ser S Threonine Thr T Glycine Gly G Alanine Ala A Valine Val V Leucine Leu L Isoleucine lie I Methionine Met M Proline Pro P Phenylalanine Phe F Tryptophan Trp W A "conservative amino acid substitution" is one in which an amino acid residue is substituted by another amino acid residue having a side chain R group with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of a protein. In cases where two or more amino acid sequences differ from each other by conservative substitutions, the percent sequence identity or degree of similarity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well-known to those of skill in the art. See, e.g., Pearson, Methods Mol. Biol. 243:307-31 ( 1994). Examples of groups of amino acids that have side chains with similar chemical properties include 1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; 2) aliphatic-hydroxyl side chains: serine and threonine; 3) amide-containing side chains: asparagine and glutamine; 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; 5) basic side chains: lysine, arginine, and histidine; 6) acidic side chains: aspartic acid and glutamic acid ; and 7) sulfur-containing side chains: cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamate-aspartate, and asparagine-glutamine. Alternatively, a conservative replacement is any change having a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al., Science 256:1 443-1 445 ( 1992), herein incorporated by reference. A "moderately conservative" replacement is any change having a nonnegative value in the PAM250 log-likelihood matrix. Preferred amino acid substitutions are those which: ( 1 ) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, and (4) confer or modify other physicochemical or functional properties of such analogs. Analogs comprising substitutions, deletions, and/or insertions can include various muteins of a sequence other than the specified peptide sequence. For example, single or multiple amino acid substitutions (preferably conservative amino acid substitutions) may be made in the specified sequence (preferably in the portion of the polypeptide outside the domain(s) forming intermolecular contacts, e.g. , outside of the CDRs or the type I or type I I receptor binding sites). A conservative amino acid substitution should not substantially change the structural characteristics of the parent sequence (e.g., a replacement amino acid should not tend to break a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterizes the parent sequence). Examples of art-recognized polypeptide secondary and tertiary structures are described in Proteins, Structures and Molecular Principles (Creighton, Ed., W. H. Freeman and Company, New York ( 1984)); Introduction to Protein Structure (C. Branden and J. Tooze, eds., Garland Publishing, New York, N.Y. ( 1991 )); and Thornton et al., Nature 354:1 05 ( 1991 ) , which are each incorporated herein by reference. The terms "polynucleotide", "nucleotide sequence", "nucleic acid", "nucleic acid molecule", "nucleic acid sequence", and "oligonucleotide" refer to a series of nucleotide bases (also called "nucleotides") in DNA and RNA, and mean any chain of two or more nucleotides. The polynucleotides can be chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded . The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, its hybridization parameters, etc. A nucleotide sequence typically carries genetic information, including the information used by cellular machinery to make proteins and enzymes. These terms include double- or single-stranded genomic and cDNA, RNA, any synthetic and genetically manipulated polynucleotide, and both sense and antisense polynucleotides. This also includes nucleic acids containing modified bases, for example, thio-uracil, thio-guanine, and fluoro-uracil, or containing carbohydrate, or lipids. In the context of a nucleotide sequence, the term "substantially identical" is used herein to refer to a first nucleic acid sequence that contains a sufficient or minimum number of nucleotides that are identical to aligned nucleotides in a second nucleic acid sequence such that the first and second nucleotide sequences encode a polypeptide having common functional activity, or encode a common structural polypeptide domain or a common functional polypeptide activity. For example, nucleotide sequences having at least about 85%, 90%, 9 1%, 92%, 93%, 94%, 95% , 96%, 97%, 98% or 99% identity to a reference sequence. By "designer BMP nucleic acids," and grammatical equivalents herein is meant nucleic acids that encode designer BMPs. The terms "protein" and "polypeptide" are used interchangeably herein. These terms refer to a sequential chain of amino acids linked together via peptide bonds. The terms include one or more proteins that function as a discrete unit. If a single polypeptide is the discrete functioning unit and does not require permanent or temporary physical association with other polypeptides in order to form the discrete functioning unit, the terms "polypeptide" and "protein" may be used interchangeably. If the discrete functional unit is comprised of multiple polypeptides that physically associate with one another, the term "protein" as used herein refers to the multiple polypeptides that are physically coupled and function together as the discrete unit. A protein to be expressed according to the present invention can be a protein therapeutic. A protein therapeutic is a protein that has a biological effect on a region in the body on which it acts or on a region of the body on which it remotely acts via intermediates. Examples of protein therapeutics are discussed in more detail below. "Designer BMP," as the term is used herein, relates to a BMP protein comprising at least one amino acid mutation compared to a corresponding wild type BMP without the mutation, wherein the designer BMP has detectably altered binding for at least a type I receptor and/or at least one type II receptor compared with the binding of the corresponding wild type BMP for the type I and/or type I I receptor. By "corresponding wild type protein" it is meant the wild type version of the designer BMP prior to the introduction of any mutations. For example, if the designer BMP is a designer BMP2, the corresponding wild-type BMP is wild-type BMP2. Thus, in one embodiment, design of a designer BMP can, but need not, begin with a wild type BMP sequence wherein mutations (e.g., amino acid substitutions, deletions and/or insertion) are introduced into the wild type sequence. Therefore, the designer BMP can correspond with a wild type BMP, and the locations of the mutations can be said , for instance, to correspond with, be relative to and/or be respective with the amino acid sequence of the wild type corresponding or "reference" BMP sequence. The proteins of the present invention include fragments, derivatives, analogs, or variants of the polypeptides described herein, and any combination thereof. The terms "fragment," "variant," "derivative" and "analog" when referring to proteins of the present invention include any proteins which retain at least some of the functional properties of the protein from which it was derived. By the term "fragment" as used herein refers to a polypeptide and is defined as any discrete portion of a given polypeptide that is unique to or characteristic of that polypeptide. The term as used herein also refers to any discrete portion of a given polypeptide that retains at least a fraction of the activity of the full-length polypeptide. In certain embodiments, the fraction of activity retained is at least 10% of the activity of the full-length polypeptide. In certain embodiments, the fraction of activity retained is at least 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% of the activity of the full-length polypeptide. In certain embodiments, the fraction of activity retained is at least 95%, 96%, 97%, 98% or 99% of the activity of the full-length polypeptide. In certain embodiments, the fraction of activity retained is 100% or more of the activity of the full-length polypeptide. Alternatively or additionally, the term as used herein also refers to any portion of a given polypeptide that includes at least an established sequence element found in the full-length polypeptide. In some embodiments, the sequence element spans at least about 4- 5, 10 , 15 , 20, 25, 30, 35, 40, 45, 50 or more amino acids of the full-length polypeptide. Fragments of proteins of the present invention include proteolytic fragments, as well as deletion fragments. Variants of the proteins of the present invention include fragments as described above, and also polypeptides with altered amino acid sequences due to amino acid substitutions, deletions, or insertions. Variants may occur naturally or be non-naturally occurring. Non-naturally occurring variants may be produced using art-known mutagenesis techniques. Variant proteins may comprise conservative or nonconservative amino acid substitutions, deletions or additions. The proteins of the invention include proteins having one or more residues chemically derivatized by reaction of a functional side group. Also included as proteins of the invention are polypeptides that contain one or more naturally occurring amino acid derivatives of the twenty standard amino acids. For example, 4-hydroxyproline may be substituted for proline; 5-hydroxylysine may be substituted for lysine; 3-methylhistidine may be substituted for histidine; homoserine may be substituted for serine; and ornithine may be substituted for lysine. "Recombinantly expressed polypeptide" and "recombinant polypeptide" as used herein refer to a polypeptide expressed from a host cell that has been manipulated to express that polypeptide. In certain embodiments, the host cell is a mammalian cell. In certain embodiments, this manipulation may comprise one or more genetic modifications. For example, the host cells may be genetically modified by the introduction of one or more heterologous genes encoding the polypeptide to be expressed. The heterologous recombinantly expressed polypeptide can be identical or similar to polypeptides that are normally expressed in the host cell. The heterologous recombinantly expressed polypeptide can also be foreign to the host cell , e.g. heterologous to polypeptides normally expressed in the host cell. In certain embodiments, the heterologous recombinantly expressed polypeptide is chimeric. For example, portions of a polypeptide may contain amino acid sequences that are identical or similar to polypeptides normally expressed in the host cell, while other portions contain amino acid sequences that are foreign to the host cell. Additionally or alternatively, a polypeptide may contain amino acid sequences from two or more different polypeptides that are both normally expressed in the host cell. Furthermore, a polypeptide may contain amino acid sequences from two or more polypeptides that are both foreign to the host cell. In some embodiments, the host cell is genetically modified by the activation or upregulation of one or more endogenous genes. Calculations of homology or sequence identity between sequences (the terms are used interchangeably herein) are performed as follows. To determine the percent identity of two amino acid sequences, or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g. , gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a typical embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50% or 60%, or at least 70%, 80%, 90%, or 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). To determine the percent identity of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g. , gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino acid or nucleic acid sequence). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e. , % homology=# of identical positions/total # of positions X 100). The determination of percent homology between two sequences can be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin et al., Proc Natl Acad Sci U S A 87:2264-8 ( 1990), modified as in Karlin et al., Proc Natl Acad Sci U S A 90:5873-7 ( 1993). Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al. , J Mol Biol 2 15:403-1 0 ( 1990). BLAST nucleotide searches can be performed with the NBLAST program , score=1 00, wordlength=1 2 . BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., Nucleic Acids Res 25:3389-402 ( 1997). When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm . In one embodiment, the percent identity between two amino acid sequences is determined using the Needleman-Wunsch algorithm (Needleman et al., J Mol Biol 48:443-53 ( 1970)) which has been incorporated into the GAP program in the GCG software package (available on at gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14 , 12 , 10 , 8 , 6 , or 4 and a length weight of 1, 2 , 3 , 4 , 5, or 6 . In yet another embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available on the internet at gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2 , 3 , 4 , 5, or 6. One typical set of parameters (and the one that should be used unless otherwise specified) are a Blossum 62 scoring matrix with a gap penalty of 12 , a gap extend penalty of 4 , and a frameshift gap penalty of 5. The percent identity between two amino acid or nucleotide sequences can be determined using the algorithm of E. Myers and W. Miller (Myers et al., Comput Appl Biosci 4:1 1-7 ( 1988)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4 . "Instructional material," as that term is used herein, includes a publication, a recording, a diagram , or any other medium of expression which can be used to communicate the usefulness of the compound, combination, and/or composition of the invention in the kit for affecting, alleviating or treating the various diseases or disorders recited herein. Optionally, or alternately, the instructional material can describe one or more methods of alleviating the diseases or disorders in a cell, a tissue, or a mammal, including as disclosed elsewhere herein. The instructional material of the kit may, for example, be affixed to a container that contains the compound and/or composition of the invention or be shipped together with a container which contains the compound and/or composition. Alternatively, the instructional material may be shipped separately from the container with the intention that the recipient uses the instructional material and the compound cooperatively. Except when noted , the terms "patient" or "subject" are used interchangeably and refer to mammals such as human patients and non-human primates, as well as veterinary subjects such as rabbits, rats, and mice, and other animals. Preferably, patient refers to a human. "Effective amount", or "therapeutically effective amount," as the terms are used interchangeably herein, is an amount that when administered to a tissue or a mammal, preferably a human, mediates a detectable therapeutic response compared to the response detected in the absence of the compound. A therapeutic response, such as, but not limited to, inhibition of and/or decreased fibrosis, increased bone mass or bone density, and the like, can be readily assessed by a plethora of art-recognized methods, including, e.g. , such methods as disclosed herein. The skilled artisan would understand that the effective amount of the compound or composition administered herein varies and can be readily determined based on a number of factors such as the disease or condition being treated , the stage of the disease, the age and health and physical condition of the mammal being treated , the severity of the disease, the particular compound being administered , and the like As used herein, to "treat" means reducing the frequency with which symptoms of a disease (e.g. , decreased bone density, fracture, fibrosis, and the like) are experienced by a patient. The term includes the administration of the compounds or agents of the present invention to prevent or delay the onset of the symptoms, complications, or biochemical indicia of a disease, alleviating the symptoms or arresting or inhibiting further development of the disease, condition, or disorder. Treatment may be prophylactic (to prevent or delay the onset of the disease, or to prevent the manifestation of clinical or subclinical symptoms thereof) or therapeutic suppression or alleviation of symptoms after the manifestation of the disease. By the phrase "specifically binds," as used herein, is meant a compound, e.g., a protein, a nucleic acid , an antibody, and the like, which recognizes and binds a specific molecule, but does not substantially recognize or bind other molecules in a sample. For instance, an BMP protein, an antibody or a peptide inhibitor which recognizes and binds a cognate receptor (e.g. , a BMP type I or type I I receptor, an antibody that binds with its cognate antigen, and the like) in a sample, but does not substantially recognize or bind other molecules in the sample. Thus, under designated assay conditions, the specified binding moiety (e.g., a BMP or a receptor binding fragment thereof) binds preferentially to a particular target molecule and does not bind in a significant amount to other components present in a test sample. A variety of assay formats may be used to select an antibody that specifically binds a molecule of interest. For example, solid-phase ELISA immunoassay, immunoprecipitation, BIAcore, FACS, Octet, and Western blot analysis are among many assays that may be used to identify a BMP that specifically reacts with a BMP receptor. Typically, a specific or selective reaction will be at least twice background signal or noise, more preferably, at least five-fold greater than background signal or noise, and more typically, more than 10 times background, even more specifically, a BMP is said to "specifically bind" a BMP receptor when the equilibrium dissociation constant (K ) is < 100 mM, more preferably < 10 mM, even more preferably < 1 mM, yet more preferably < 100 nM and most preferably < 10 nM. The term "K " refers to the equilibrium dissociation constant of a particular ligand-receptor interaction. "Binding affinity" generally refers to the strength of the sum total of noncovalent interactions between a binding site of a molecule (e.g. , a BMP ligand) and its binding partner (e.g., a BMP type I or type I I receptor). Unless indicated otherwise, as used herein, "binding affinity" refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g., BMP and its cognate receptor). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (Kd). Affinity can be measured by common methods known in the art, including those described herein. Low-affinity BMPs generally bind a receptor slowly and tend to dissociate readily, whereas high-affinity BMPs generally bind a receptor faster and tend to remain bound longer. A variety of methods of measuring binding affinity are known in the art, any of which can be used for purposes of the present invention. Specific illustrative embodiments are described elsewhere herein. The term "ko " , as used herein is intended to refer to the association or on rate constant, or specific reaction rate, of the forward, or complex-forming, reaction, measured in units: M~ sec 1 . The term "koff" , as used herein, is intended to refer to the dissociation or off rate constant, or specific reaction rate, for dissociation of an antibody from the antibody/antigen complex, measured in units: sec 1 . The term "Kd" , as used herein, is intended to refer to the dissociation constant of a particular antibody-antigen interaction. It is calculated by the formula: The term "altered binding" as used herein means the designer BMP comprises a different binding specificity for at least a type I receptor and/or a type I I receptor when compared with the binding of a corresponding wild type BMP to the same type I and/or type I I receptor. The designer BMP may bind with greater or lesser affinity with the receptor compared to the binding of the wild type BMP to that receptor. For instance, if the wild type BMP bound a certain type I receptor with a certain binding affinity, the corresponding designer BMP binds that receptor with greater or lesser affinity compared with the wild type BMP. It may even be that the designer BMP will specifically bind a receptor that the wild type BMP did not detectably bind and vice-a-versa where the designer BMP will no longer detectably bind a receptor that the wild type BMP binds. Thus, altered binding encompasses any detectable change in binding by a designer BMP to a type I or type I I receptor compared with the binding of that receptor by the corresponding wild type BMP. It may be that the designer BMP has a greater or lesser ko value compared with the ko value for a corresponding wild type BMP and/or the designer BMP has a greater or lesser koff value compared with the koff value of the corresponding wild type BMP such that the Kd of the designer BMP is greater or lesser than the Kd of a corresponding wild type BMP for the same BMP receptor. Thus, any difference in a binding characteristic and/or affinity value between a designer BMP and a corresponding wild type BMP are encompassed by the term "altered binding" as used herein. The term "surface plasmon resonance", as used herein, refers to an optical phenomenon that allows for the analysis of real-time biospecific interactions by detection of alterations in protein concentrations within a biosensor matrix, for example using the BIAcore system (Pharmacia Biosensor AB, Uppsala, Sweden, and Piscataway, N.J .). For further descriptions, see, e.g., Johnsson, et al., Ann. Biol. Clin. 5 1: 19-26 ( 1993); Johnsson, et al., Biotechniques 11: 620-627 ( 1991 ) ; Johnsson, et al. , J. Mol. Recognit. 8 : 125-1 3 1 ( 1995); and Johnnson, et al., Anal. Biochem. 198: 268-277 ( 1991 ) . As used herein, "substantially pure" means an object species is the predominant species present (i.e. , on a molar basis it is more abundant than any other individual species in the composition), and preferably a substantially purified fraction is a composition wherein the object species (e.g., a designer BMP) comprises at least about 50 percent (on a molar basis) of all macromolecular species present. Generally, a substantially pure composition will comprise more than about 80 percent of all macromolecular species present in the composition, more preferably more than about 85%, 90%, 95%, and 99%. Most preferably, the object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single macromolecular species. Description Bone Morphoqenetic Proteins (BMPs) As stated previously elsewhere herein, BMPs are members of the TGF- b protein superfamily all of which are characterized by six-conserved cysteine residues (Lander et al, (2001 ) Nature, 409:860-921 . The BMP/GDF subfamily includes, but is not limited to, BMP2 , BMP3 (osteogenin) (see, e.g., US Patent No. 6,177,406), BMP3b (GDF-1 0) (see, e.g., US Patent No. 6,204,047), BMP4 (BMP2b) (see, e.g., US Patent No. 6,245,889), BMP5 (see, e.g., US Patent No. 5,543,394), BMP6 (see, e.g., US Patent No. 6,61 3,744), BMP7 (osteogenic protein-1 or OP1 ) (see, e.g., US Patent No. 5,14 1,905), BMP8 (OP2) (see, e.g., US Patent No. 5,688,678), BMP8B (OP3) (see, e.g., US Patent No. 5,854,071 ) , BMP9 (GDF2) (see, e.g., US Patent No. 6,287,81 6), BMP1 0 (see, e.g., US Patent No. 5,703,043), BMP1 1 (GDF1 1) (see, e.g., US Patent No. 6,437,1 11) , BMP1 2 (GDF7) (see, e.g., US Patent No. 6,027,91 9), BMP1 3 (GDF6, CDMP2) (see, e.g., US Patent No. 6,027,91 9), BMP1 5 (GDF9) (see, e.g., US Patent No. 6,034,229), BMP1 6 (see, e.g., US Patent No. 6,331 ,61 2), GDF1 (see, e.g., US Application No. 2004/00391 62), GDF3 (see, e.g., US Patent No. 6,025,475), GDF5 (CDMP1 ; MP52) (see, e.g., US Patent No. 5,994,094), and GDF8 (myostatin) (see, e.g., US Patent No. 5,827,733). BMPs specifically bind their cognate receptors, which include Type I receptors: ALK-I, ALK-2 (also called ActRIa or ActRI), ALK-3 (also called BMPRIa), and ALK-6 (also called BMPRIb); and Type I I receptors: ActRMa (also called ActRII), ActRllb, and BMPRI I . The BMP-receptor binding interactions have been studied extensively, and the binding specificities of each wild type BMP for each type I and/or type I I receptor is generally known in the art and are shown in Table 1. See, e.g. , Nickel et al., Cytokine Growth Factor Rev 20:367-77 (2009); Heinecke et al., BMC Biol 7:59 (2009). TABLE 1 ALK 1 ALK 2 ALK 3 ALK 6 ACTI IA ACTIIB BMPRII BMP-7 No Binding No Binding ++ ++ ++++ ++++ ++++ BMP-9 +++++ No Binding No Binding No Binding ++ +++ ++++ Designer Bone Morphoqenetic Proteins with Improved Osteogenic Activity This application is based , in part on the understanding that each BMP dimer binds to four BMP receptors two type I receptors and two type I I receptors. The specificities of each BMP for each receptor are known in the art as shown above in Table 1. Also, the receptor binding regions of various BMPs that mediate binding of the BMP for each receptor have been mapped and are shown in Table 2 . For instance, it is well established that wild type BMP2 and BMP4 bind type I BMP receptors Alk-3 and ALK-6 with high affinity and bind type I I BMP receptors with lower affinity. On the other hand , wild type BMP6 and BMP7 are known to have bind type I I receptors Actrl lA, Actrl lB, and BMPRI I with high affinity but bind type I receptors with lower affinity than they do to type II. It is believed that the differing cellular responses from the approximately forty-three TGFp superfamily members signaling through interaction with approximately twelve receptors is believed to be due to each ligand utilizing a specific repertoire of receptors with which it binds with differing affinities. The type I and II binding domains are described in Table 2 . TABLE 2 Rational amino acid substitution to alter receptor binding of designer BMPs In one embodiment, the invention comprises introducing an amino acid mutation in at least one receptor binding site thereby providing altered binding to type I and type I I BMP receptors by designer BMPs compared to the binding of the corresponding wild type BMP to those receptors. That is, it is well known in the art that wild type BMP2 shows a relatively high affinity for type I receptors, while wild type BMP6 shows a high affinity for type I I receptors. It is further known in the art that heterodimers of wild type BMP2 and BMP6 bind to both type I and type II receptors with relatively high affinity each BMP apparently providing the higher affinity binding site for each receptor. See Table 3, below. The BMP2/6 heterodimers are known to be more active that BMP2 or BMP6 alone or as homodimers, in both in vitro and in vivo bone formation assays. Table 3 shows an example of BMP2 and BMP6 binding affinities to type I and I I receptors. TABLE 3 Accordingly, it is an object of the invention to provide designer BMPs with improved binding to type I and/or type I I receptors. As shown in Figure 1A and Table 2 , each BMP comprises three binding sites that contribute to receptor binding. From N- to C-terminus, each BMP comprises a type I I receptor binding site A, a type I receptor binding site, and a second type I I receptor binding site B. Although an exemplary alignment of wild type BMP2, BMP4, BMP5, BMP6, BMP7, BMP8, and BMP9 is illustrated in Figure 1, the skilled artisan will appreciate that there are well-known alignments providing the relative positioning of various amino acids among the members of the TQBb superfamily. Such alignments are provided , among others, in International Publication Nos. WO 2009/0861 3 1 (e.g. , Figures 15-1 7, Figure 31A), WO 2008/051 526 (Figures 9-1 2), WO 2005/1 18636 (Figure 6), WO 2005/1 18635, WO 2005/1 13585 (Figure 3), WO 2001 /92298 (Figure 6A-6C), Kirsch et al. , EMBO J. 19 :331 4-3324 (2000) (Figure 1) , US Patent Application Publication No., 2007/0293425 (Figure 6), Groppe et al., Nature 420 :636-642 (2002), Nickel et al., J. Bone Joint Surg. Am. 83:7-1 4 (2001 ) , and Weber et al. , BMC Structural Biol. 7 :6 (2007). Thus, using protein sequence alignment algorithms and tools well-known in the art, including the alignments of the amino acid sequences of the various TGFp superfamily members, as well as the disclosure provided herein, the corresponding amino acid in one BMP/GDF protein relative to the amino acid at any position in another BMP/GDF protein can be determined. In one embodiment, the corresponding amino acid residues in BMP-2, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8 and BMP-9 are shown (see, e.g. , Figure 1A). In some embodiments of the invention, the designer BMP comprises mutations in a type I binding domain or a type I I binding domain, wherein the mutations confer altered binding to a type I or type I I BMP receptor. In some embodiments, the designer BMP comprises one or more mutations in both a type I binding domain and a first (binding domain A) or second (binding domain B) type I I binding domain. In other embodiments, the designer BMP comprises one or more mutations in both type I I binding domains. In other embodiments, the designer BMP comprises one or more mutations in the first type I I binding domain, in the second type I I binding domain, and in the type I binding domain. In some embodiments, the designer BMP comprises one or more mutations in the type I binding domain. In some embodiments, the mutations improve binding to a type I receptor. In other embodiments, the mutations improve binding to a type I I receptor. In other embodiments, the mutations decrease binding to a type I or type I I receptors. In some embodiments, the mutations create or destroy a glycan tether as more fully set forth below. In some embodiments, the mutations create or destroy a His doorstop as more fully set forth below. Because BMPs are so well characterized and understood in the art, it would be understood , once provided with the disclosure provided herein, the location of possible mutations that can be made that do not further affect the activity of the designer BMPs would be understood . Accordingly, the designer BMPs of the invention encompass variant BMPs which differ from a corresponding wild type or designer BMP in that it contains additional insertions, deletions, or substitutions which do not affect the receptor binding affinity of the variant BMPs. In some non-limiting embodiments, those of skill in the art would understand that the cysteines involved in cysteine knot formation and amino acids involved in receptor interactions should not be mutated or should be changed with conservative substitutions, while other amino acids may be more freely substituted , inserted, or deleted without adversely affecting biological activity of the designer BMP. It should be noted that unless otherwise stated, all positional numbering of designed or modified BMPs is based on the sequences of the mature native BMPs. Designer BMPs are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the BMP sequence. Variants of designer BMPs must retain at least 50% of the activity of the corresponding wild type or designer BMP activity in one or more cell types, as determined using an appropriate assay described below. Variants that retain at least 75%, 80%, 85% , 90% or 95% of wild type activity are more preferred, and variants that are more active than wild type are especially preferred. A designer BMP may contain insertions, deletions, and/or substitutions at the N- terminus, Cterminus, or internally. In a preferred embodiment, designed or modified BMPs have at least 1 residue that differs from the most similar human BMP sequence, with at least 2 , 3 , 4 , 5, 6, 7, 8 , 9 , 10 or more different residues being more preferred . Designer BMPs of the invention maintain at least 80% , at least 8 1%, at least 82%, at least 83%, at least 84% , at least 85%, at least 86%, at least 87% , at least 88%, at least 89%, at least 90%, at least 9 1%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the corresponding wild-type BMP protein sequence. Designer BMPs of the invention may maintain at least 80%, at least 8 1%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 9 1%, at least 92%, at least 93%, at least 94% , at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the conserved cysteine domain of the C-terminal region of the corresponding wild-type BMP protein sequence. Designer BMPs may contain further modifications, for instance mutations that alter additional protein properties such as stability or immunogenicity or which enable or prevent posttranslational modifications such as PEGylation or glycosylation. Designer BMPs may be subjected to co- or post¬ translational modifications, including but not limited to synthetic derivatization of one or more side chains or termini, glycosylation, PEGylation, circular permutation, cyclization, fusion to proteins or protein domains, and addition of peptide tags or labels. Due to the degeneracy of the genetic code, an extremely large number of nucleic acids may be made, all of which encode the designer BMPs of the present invention, by simply modifying the sequence of one or more codons in a way that does not change the amino acid sequence of the designer BMP. The designer BMPs of the invention do not comprise these sequences set forth in WO2008/051 526 or WO2009/0861 3 1. As described above, BMPs are naturally expressed as pro-proteins comprising a long prodomain, one or more cleavage sites, and a mature domain. This pro-protein is then processed by the cellular machinery to yield a dimeric mature BMP molecule. In a preferred embodiment, the designer BMPs of the invention are produced in a similar manner. The pro-domain is believed to aid in the correct folding and processing of BMPs. Furthermore, in some but not all BMPs, the pro-domain may noncovalently bind the mature domain and may act as a chaperone, as well as an inhibitor (e.g., Thies et al. (2001 ) Growth Factors, 18:251 -259). Preferably, the modified BMPs of the invention are produced and/or administered therapeutically in this form. Alternatively, BMPs may be produced in other forms, including, but not limited to, where the mature domain is produced directly or refolded from inclusion bodies, or comprises full-length intact pro protein. The designer BMPs of the invention will be useful in these and other forms. In particular embodiments, the designer BMP of the invention comprises a backbone BMP, i.e. , the wild type BMP, to which the designer BMP corresponds. In particular embodiments, this backbone BMP may be a wild type BMP2, BMP4, BMP5, BMP6, BMP7, BMP8, or BMP9 backbone. In some embodiments of the invention, the designer BMP comprises at least one mutation in a type I binding domain and/or a type I I binding domain, wherein the mutation confers altered binding to a type I or type I I BMP receptor compared with the binding of a corresponding wild type BMP not comprising the mutation. In some embodiments, the designer BMP comprises at least one mutation in both a type I binding domain and at least one mutation in a type II binding domain. In other embodiments, the designer BMP comprises at least one mutation within the type I I binding domain A and the type I I binding domain B. In other embodiments, the designer BMP comprises at least one mutation in type I I binding domain A, type I I binding domain B, and a type I binding domain. In certain embodiments, the mutation may comprise an amino or nucleic acid substitution, deletion and/or insertion. In a preferred embodiment, the mutation comprises an amino acid substitution. In some embodiments, the backbone BMP is a wild type BMP and the mutations are one or more of the mutations listed in Tables 4 to 6 . The designer BMP may contain any combination and any number of mutations listed in these tables. In some embodiments, the backbone BMP is a wild type BMP and the mutations are one or more of the mutations listed in Tables 4 to 6. The designer BMP may contain a permutation and any and all of the mutations listed in these tables or disclosed elsewhere herein. TABLE 4 TABLE 5 P36 P38 E59 K60 E60 Q60 K30 K, R, P, E, Q G37 G39 G60 G61 G61 G61 E31 G, E H39 Q41 A62 A63 A63 S63 E33 A, E, S, Q F41 F43 F64 N65 Y65 Y65 Y35 N, Y, F Y42 Y44 Y65 Y66 Y66 Y66 E36 Y, E H44 H46 D67 D68 E68 E68 K38 H, D, K, R, E TABLE 6 Type I I Binding Domain B Mutations BMP2 BMP4 BMP5 BMP6 BMP7 BMP8 BMP9 Possible mutations E83 E85 K 107 K 108 Q 108 K 108 K78 Q, K, E S85 S87 N 109 N 110 N 110 S 110 S80 N, S A86 A88 A 110 A 111 A 111 A 111 P81 P, A M89 M91 V 113 V 114 V 114 V 114 V84 M, V L92 L94 F 116 F 117 F 117 Y 117 K87 F, K, L, Y E94 E96 D 118 D 119 D 119 D 118 D89 D, E N95 Y97 S 119 N 120 S 120 S 119 M90 M, N, S E96 D98 S 120 S 12 1 S 12 1 S 120 G91 S, G, D K97 K99 N 12 1 N 122 N 122 N 12 1, V92 N, V, K N 122 V98 V 100 V 122 V 123 V 123 V 123 P93 P, V V99 V 10 1 11 23 11 24 11 24 11 24 T94 T, I , V In some embodiments, the mutations improve binding to a type I receptor. In other embodiments improve binding to a type II receptor. In other embodiments, the mutations decrease binding to a type I or type I I receptors. Tables 4-6 above provide a non-limiting compilation of example mutations of the present invention where the position of the mutation is provided relative to the corresponding wild type BMP amino acid sequence. Thus, in some embodiments, the designer BMP comprises the following preferred combinations of mutations. In certain embodiments, the corresponding wild type BMP to the designer BMP is BMP2. Further, the at least one mutation within the type I I receptor binding domain A is a mutation selected from the group consisting of V33, P36, G37, H39, F41 , Y42 AND H44. In other embodiments, the designer BMP comprises at least one mutation within the type I I receptor binding domain A and further comprises at least one additional mutation within a type I receptor binding domain. The mutation within the type I receptor binding domain is at least one mutation at P48, F49, A52, D53, H54, L55, N56, S57, N59, V63, T65, N68, S69, V70, N71 , S72, K73, I74, and P75 with respect to the sequence of SEQ ID NO:1 . In yet further embodiments, the designer BMP comprises at least one mutation within a type I I receptor binding domain A, at least one mutation within the type I receptor binding domain, and further comprises at least one additional mutation within a type MB receptor binding domain. The mutation within the type II receptor binding domain B is at least one mutation at E83, S85, A86, M89, L92, E94, N95, E96, K97, V98, and V99 with respect to the sequence of SEQ ID NO: 1. In some embodiments, the designer BMP comprises mutations at each of amino acids H44, P48, A52, D53, L55, S57, N68, S69, V70, insertion of P after N71 , S72, K73, I74, A77, and V80 with respect to the sequence of SEQ ID NO:1 . In one embodiment, the designer BMP comprises the following mutations: H44D, P48S, A52N, D53A, L55M, S57A, N68H, S69L, V70M, insertion of a P after N71 , S72E, K73Y, I74V, A77P, and V80A with respect to the sequence of SEQ ID NO:1 . In some embodiments the designer BMP comprises mutations at each of amino acids V33, P36, H39, S85, M89, L92, E94, E96, K97, and V99 with respect to the sequence of SEQ ID NO:1 . In some embodiments, the designer BMP comprises mutations at each of amino acids V33I, P36K, H39A, S85N, M89, L92F, E94D, E96S, K97N, and V99I with respect to the sequence of SEQ ID NO: 1. In other embodiments, the designer BMP comprises the following mutations: V33I, P36K, H39A, H44D, P48S, A52N, L54M, S56M, N68H, V70M, S72E, K73E, insertion of a Y after K73, I74V, 77AP, S85N , M89V, L92F, E94D, E96S, K97N , and V99I with respect to the sequence of SEQ ID NO:1 . In yet other embodiments, the designer BMP comprises the following mutations: V33I, P36R, H39A, H44D, P48S, A52N , L54M, S56M, N68H, V70M, S72E, K73E, insertion of a Y after K73, I74V, 77AP, S85N, M89V, L92F, E94D, E96S, K97N, and V99I with respect to the sequence of SEQ ID NO: 1. In certain embodiments, the corresponding wild type BMP to the designer BMP is BMP4. In certain embodiments, the at least one mutation within the type II receptor binding domain A is at V35, P38, G39, Q41 , F43, Y44, and H46 of SEQ ID NO:2. In other embodiments, the designer BMP4 comprises at least one mutation within the type I I receptor binding domain A and further comprises at least one additional mutation within a type I receptor binding domain. The mutation within the type I receptor binding domain is at least one mutation at P50, A54, D55, H56, L57, N58, S59, N61 , V65, T67, N70, S71 , V72, N73, S74, S75, I76, and P77 of SEQ ID NO:2. In yet further embodiments, the designer BMP4 comprises at least one mutation within a type I I receptor binding domain A, at least one mutation within the type I receptor binding domain, and further comprises at least one additional mutation within a type MB receptor binding domain. The mutation within the type I I receptor binding domain B is at least one mutation at E85, S87, A88, M91 , L94, E96, K97, V98 and V99 of SEQ ID NO:2. In certain embodiments, the corresponding wild type BMP to the designer BMP is BMP5. In certain embodiments, the mutation within the type I I receptor binding domain A is at least one mutation at 156, E59, G60, A62, F64, Y65, or D67 of SEQ ID NO:3. In other embodiments, the designer BMP comprises at least one mutation within the type I I receptor binding domain A and further comprises at least one additional mutation within a type I receptor binding domain. The mutation within the type I receptor binding domain is at least one mutation at S71 , F72, N75, A76, H77, M78, N79, A80, N82, V86, T88, H91 , L92, M93, F94, P95, D96, H97, V98, or P99 of SEQ ID NO:3. In yet further embodiments, the designer BMP comprises at least one mutation within a type I I receptor binding domain A , at least one mutation within the type I receptor binding domain, and further comprises at least one additional mutation within a type MB receptor binding domain. The mutation within the type I I receptor binding domain B is at least one mutation at K 107, N 109, A 110 , V 113 , F 116, D 118 , S 119 , S 120, N 12 1, V 122, or 11 23 of SEQ ID NO:3. In certain embodiments, the corresponding wild type BMP to the designer BMP is BMP6. In certain embodiments, the mutation within the type I I receptor binding domain A is at least one mutation at 157, K60, G61 , A63, N65, Y66, or D68 of SEQ ID NO:4. In other embodiments, the designer BMP6 comprises at least one mutation within the type I I receptor binding domain A and further comprises at least one additional mutation within a type I receptor binding domain. The mutation within the type I receptor binding domain is at least one mutation at S72, N76, A77, H78, M79, N80, A81 , N83, V87, T89, H92, L93, M94, N95, P96, E97, Y98, V99, or P 100 of SEQ ID NO:4. In yet further embodiments, the designer BMP6 comprises at least one mutation within a type I I receptor binding domain A , at least one mutation within the type I receptor binding domain, and further comprises at least one additional mutation within a type MB receptor binding domain. The mutation within the type I I receptor binding domain B is at least one mutation at K 108, N 110 , A 111, V 114 , F 117, D 119 , N 120, S 12 1, N 122, V 123, or 11 24 of SEQ ID NO:4. In certain embodiments, the corresponding wild type BMP to the designer BMP is BMP7. In certain embodiments, the mutation within the type I I receptor binding domain A is at least one mutation at I57, E60, G61 , A63, Y65, Y66, or E68 of SEQ ID NO:5. In other embodiments, the designer BMP7 comprises at least one mutation within the type I I receptor binding domain A and further comprises at least one additional mutation within a type I receptor binding domain. The mutation within the type I receptor binding domain is at least one mutation at A72, F73, N76, S77, Y78, M79, N80, A81 , N83, V87, T89, H92, F93, I94, N95, P96, E97, T98, V99, or P 100 of SEQ ID NO:5. In yet further embodiments, the designer BMP7 comprises at least one mutation within a type I I receptor binding domain A , at least one mutation within the type I receptor binding domain, and further comprises at least one additional mutation within a type MB receptor binding domain. The mutation within the type I I receptor binding domain B is at least one mutation at Q 108, N 110 , A 111, V 114 , F 117, D 119 , S 120, S 12 1, N 122, V 123, or 11 24 of SEQ ID NO:5. In certain embodiments, the corresponding wild type BMP to the designer BMP is BMP8. In certain embodiments, the mutation within the type I I receptor binding domain A is at least one mutation at I57, Q60, G61 , S63, Y65, Y66, or E68 of SEQ ID NO:6. In other embodiments, the designer BMP8 comprises at least one mutation within the type I I receptor binding domain A and further comprises at least one additional mutation within a type I receptor binding domain. The mutation within the type I receptor binding domain is at least one mutation at S72, F73, D76, S77, C78, M79, N80, A82, N83, L87, S89, H92, L93, M94, M95, P96, D97, A98, V99, or P 100 of SEQ ID NO:6. In yet further embodiments, the designer BMP8 comprises at least one mutation within a type I I receptor binding domain A, at least one mutation within the type I receptor binding domain, and further comprises at least one additional mutation within a type MB receptor binding domain. The mutation within the type I I receptor binding domain B is at least one mutation at K 108, S 110 , A 111, V 114 , Y 117, D 118 , S 119 , S 120, N 12 1, N 122, V 123, or 11 24 or SEQ ID NO:6 In certain embodiments, the mutation within the type II receptor binding domain A is at least one mutation at I27, K30, E31 , E33, Y35, or E36 of SEQ ID NO:7. In other embodiments, the designer BMP9 comprises at least one mutation within the type I I receptor binding domain A and further comprises at least one additional mutation within a type I receptor binding domain. The mutation within the type I receptor binding domain is at least one mutation at F42, F43, A46, D47, D48, V49, T50, P51 , K53, V57, T59, H62, L63, K64, F65, P66, T67, K68, V69, or G70 of SEQ ID NO:7. In yet further embodiments, the designer BMP9 comprises at least one mutation within a type I I receptor binding domain A, at least one mutation within the type I receptor binding domain, and further comprises at least one additional mutation within a type MB receptor binding domain. The mutation within the type I I receptor binding domain B is at least one mutation at K78, S80, P81 , V84, K87, D89, M90, G91 , V92, P93, or T94 of SEQ ID NO:7. Exemplary amino acid sequences of designer BMPs are set forth in Table 7, below. Table 7 shows the name and sequence of the designed molecules. TABLE 7 NAME SEQUENCE SEQ ID NO BMP-E QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCDGECSFPLNAHMNATNHAIVQTLVH 12 LMNPEYVPKPCCAPTELSAISMLYLDENEKWLKNYQDMWEGCGCR BMP-F QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWI IAPKGYAAFYCHGECPFPLADHLNSTNHAIVQTLVN 13 SVNSKIPKACCVPTELSAISMLYLDENEKWLKNYQDMWEGCGCR BMP-G QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWI IAPKGYAAFYCHGECPFPLADHLNSTNHAIVQTLVN 14 SVNSKIPKACCVPTELNAISVLYFDDNSNVILKNYQDMWEGCGCR BMP-H QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWI IAPKGYHAFYCHGECPFPLADHLNSTNHAIVQTLVN 15 SVNSKIPKACCVPTELNAISVLYFDENSNWLKKYQDMWRGCGCR BMP-I QAKHKQRKRLKSSCKRHELYVSFQDLGWQDWI IAPKGYAANYCHGECPFPLADHLNSTNHAIVQTLVN 16 SVNSKIPKACCVPTELNAISVLYFDDNSNVILKKYRNMWRACGCR BMP-J QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWI IAPKGYHAFYCDGECSFPLNAHMNATNHAIVQTLVH 17 LMNPEYVPKPCCAPTELNAISVLYFDENSNWLKKYQDMWRGCGCR BMP-K QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTKHAIVQTLVN 18 SVNSKIPKACCVPTELSAISMLYLDENEKWLKNYQDMWEGCGCR BMP-T QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTTHAIVQTLVN 19 SVNSKIPKACCVPTELSAISMLYLDENEKWLKNYQDMWEGCGCR BMP-AP QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWI IAPPGYAANYCHGECPFPLADHLNSTNHAIVQTLVN 20 SVNSKIPKACCVPTELSAISMLYLDENEKWLKNYQDMWEGCGCR BMP-AR QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWI IAPRGYAANYCHGECPFPLADHLNSTNHAIVQTLVN 2 1 SVNSKIPKACCVPTELSAISMLYLDENEKWLKNYQDMWEGCGCR BMP-AK QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWI IAPKGYAANYCHGECPFPLADHLNSTKHAIVQTLVN 22 SVNSKIPKACCVPTELSAISMLYLDENEKWLKNYQDMWEGCGCR BMP-AT QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWI IAPKGYAANYCHGECPFPLADHLNSTTHAIVQTLVN 23 SVNSKIPKACCVPTELSAISMLYLDENEKWLKNYQDMWEGCGCR BMP-DP QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLNAHMNATNHAIVQTLVH 24 LMNPSKIPKACCVPTELSAISMLYLDENEKWLKNYQDMWEGCGCR BMP-E9 QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCKGGCFFPLADDVTPTKHAIVQTLVH 25 LKFPTKVGKACCVPTELSAISMLYLDENEKWLKNYQDMWEGCGCR BMP- QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCRGVCNYPLAEHLTPTKHAI IQALVH 26 E 10 LKNSQKASKACCVPTELSAISMLYLDENEKWLKNYQDMWEGCGCR BMP-EK QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCDGECSFPLNAHMNATKHAIVQTLVH 27 LMNPEYVPKPCCAPTELSAISMLYLDENEKWLKNYQDMWEGCGCR BMP-ET QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCDGECSFPLNAHMNATTHAIVQTLVH 28 LMNPEYVPKPCCAPTELSAISMLYLDENEKWLKNYQDMWEGCGCR BMP-R QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPRGYHAFYCHGECPFPLADHLNSTNHAIVQTLVN 29 SVNSKIPKACCVPTELSAISMLYLDENEKWLKNYQDMWEGCGCR BMP-G5 QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCEGLCEFPLRSHLEPTNHAVIQTLMN 30 SMDPESTPPTCCVPTELSAISMLYLDENEKWLKNYQDMWEGCGCR BMP-ER QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPRGYHAFYCHGECPFPLADHLNSTNHAIVQTLVN 3 1 SVNSKIPKACCVPTELSAISMLYLDENEKWLKNYQDMWEGCGCR BMP-GP QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWI IAPPGYAAFYCHGECPFPLADHLNSTNHAIVQTLVN 32 SVNSKIPKACCVPTELNAISVLYFDDNSNVILKNYQDMWEGCGCR BMP- QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWI IAPRGYAAFYCHGECPFPLADHLNSTNHAIVQTLVN 33 GR SVNSKIPKACCVPTELNAISVLYFDDNSNVILKNYQDMWEGCGCR BMP-GK QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWI IAPKGYAAFYCHGECPFPLADHLNSTKHAIVQTLVN 34 SVNSKIPKACCVPTELNAISVLYFDDNSNVILKNYQDMWEGCGCR BMP-GT QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWI IAPKGYAAFYCHGECPFPLADHLNSTTHAIVQTLVN 35 SVNSKIPKACCVPTELNAISVLYFDDNSNVILKNYQDMWEGCGCR BMP-GE QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWI IAPKGYAAFYCDGECSFPLNAHMNATNHAIVQTLVH 36 LMNPEYVPKPCCAPTELNAISVLYFDDNSNVILKNYQDMWEGCGCR BMP-GE QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWI IAPRGYAAFYCDGECSFPLNAHMNATNHAIVQTLVH 37 R LMNPEYVPKPCCAPTELNAISVLYFDDNSNVILKNYQDMWEGCGCR BMP-JP QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWI IAPPGYHAFYCDGECSFPLNAHMNATNHAIVQTLVH 38 LMNPEYVPKPCCAPTELNAISVLYFDENSNWLKKYQDMWRGCGCR BMP-JR QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWI IAPRGYHAFYCDGECSFPLNAHMNATNHAIVQTLVH 39 LMNPEYVPKPCCAPTELNAISVLYFDENSNWLKKYQDMWRGCGCR BMP-JK QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWI IAPKGYHAFYCDGECSFPLNAHMNATKHAIVQTLVH 40 LMNPEYVPKPCCAPTELNAISVLYFDENSNWLKKYQDMWRGCGCR BMP-JT QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWI IAPKGYHAFYCDGECSFPLNAHMNATTHAIVQTLVH 4 1 LMNPEYVPKPCCAPTELNAISVLYFDENSNWLKKYQDMWRGCGCR BMP-A9 QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWI IAPKEYEAYECHGECPFPLADHLNSTNHAIVQTLVN 42 SVNSKIPKACCVPTELSAISMLYLDENEKWLKNYQDMWEGCGCR

NAME SEQUENCE SEQ ID NO CH BMP9E2 REKRSAGAGSHCQKTSLRVNFEDIGWDSWI IAPKEYEAYECHGECPFPLADHLNSTNHAIVQTLVNSV 65 NSKI PKACCVPTKLSPISVLYKDDMGVPTLKYHYEGMSVAECGCR BMP9E6 SAGAGSHCQKTSLRVNFEDIGWDSWI IAPKEYEAYECDGECSFPLNAHMNATNHAIVQTLVHLMNPEY 66 VPKPCCAPTKLS PISVLYKDDMGVPTLKYHYEGMSVAECGCR BMP6- VSSASDYNSSELKTACRKHELYVSFQDLGWQDWI IAPKGYAANYCDGECSFPLNAHMNATNHAIVQTL 67 Short VHLMNPEYVPKPCCAPTKLNAISVLYFDDNSNVILKKYRNMWRACGCH BMP6- VSSASDYNSSELKTACRKHELYVSFQDLGWQDWI IAPKGYAANYCDGECSFPLNAAMNATNHAIVQTL 68 SA VHLMNPEYVPKPCCAPTKLNAISVLYFDDNSNVILKKYRNMWRACGCH BMP6- VSSASDYNSSELKTACRKHELYVSFQDLGWQDWI IAPKGYAANYCDGECSFPLNAHLNATNHAIVQTL 69 SL VHLMNPEYVPKPCCAPTKLNAISVLYFDDNSNVILKKYRNMWRACGCH BMP-E- QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCDGECSFPLNAHMNATNHAIVQTLVH 70 NR LMNPEYVPKPCCAPTELSAISMLYLDENEKWLKNYQDMWEGCGCR BMP- QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWI IAPRGYAAFYCDGECSFPLNAHMNATNHAIVQTLVH 7 1 GER-NR LMNPEYVPKPCCAPTKLRPMSMLYYDDGQNI IKKDIQNMIVEECGCS BMP-E- QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCDGECSFPLNAHMNATNHAIVQTLVH 72 NR-6 LMNPEYVPKPCCAPTKLNAISVLYFDDNSNVILKKYRNMWRACGCH BMP- QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWI IAPRGYAAFYCDGECSFPLNAHMNATNHAIVQTLVH 73 GER- LMNPEYVPKPCCAPTKLNAISVLYFDDNSNVILKKYRNMWRACGCH NR-6 Although the above listed designer BMPs comprise embodiments of the invention, the invention is not limited in any way to any specific molecules. Instead, the invention encompasses any designer BMP comprising altered receptor binding where the designer BMP comprises at least one mutation within a type I I receptor binding domain A, even more preferably, the designer BMP comprises at least one further mutation within a type I receptor binding domain, most preferably, the designer BMP comprises yet another at least one further mutation within a type II receptor binding domain B. In other embodiments, the designer BMP of the present invention comprises an amino acid sequence at least about 70%, 75% , 80%, 85%, 87% , 90%, 92%, 95%, 96%, 97%, 98%, 99% or identical to one of the sequences described above. In another embodiment, the designer BMP comprises an amino acid sequence at least about 70%, 75%, 80%, 85%, 87%, 90%, 92%, 95%, 96% , 97%, 98%, 99% or identical to the sequence of SEQ ID NOs:8-73. In yet another embodiment, the designer BMP comprises an amino acid sequence as set forth in any one of SEQ ID NOs:8-73. In another embodiment, the amino acid sequence of the designer BMP consists of one of the sequences of SEQ ID NOs:8-73. Further, in one embodiment, the designer BMP comprises an amino acid sequence at least about 70%, 75%, 80%, 85%, 87%, 90%, 92% , 95%, 96%, 97%, 98%, 99% or identical to the sequence of SEQ ID NO:1 2 . In another embodiment, the amino acid sequence is the sequence of SEQ ID NO: 12 . In yet another embodiment, the designer BMP is BMPE. In an additional embodiment, the designer BMP comprises an amino acid sequence at least about 70%, 75%, 80%, 85%, 87% , 90%, 92%, 95%, 96%, 97%, 98%, 99% or identical to the sequence of SEQ ID NO: 14 . In another embodiment, the amino acid sequence is the sequence of SEQ ID NO:1 4 . In yet another embodiment, the designer BMP is BMPG. In another embodiment, the designer BMP comprises an amino acid sequence at least about 70%, 75%, 80%, 85%, 87%, 90%, 92% , 95%, 96%, 97%, 98%, 99% or identical to the sequence of SEQ ID NO:36. In another embodiment, the amino acid sequence is the sequence of SEQ ID NO:36. In yet another embodiment, the designer BMP is BMPGE. In another embodiment, the designer BMP comprises an amino acid sequence at least about 70%, 75%, 80%, 85%, 87%, 90%, 92% , 95%, 96%, 97%, 98%, 99% or identical to the sequence of SEQ ID NO:37. In another embodiment, the amino acid sequence is the sequence of SEQ ID NO:37. In yet another embodiment, the designer BMP is BMPGER. A designer BMP of the invention may comprise a fragment of any one of the sequences described above. In an embodiment, a designer BMP fragment may comprise a fragment of at least an uninterrupted 20, 22, 24, 25, 26, 27, 28, 30, 32, 33, 34, 35, 36, 37, 38, 40, 4 1, 43, 44, 45, 47, 50, 53, 54, 56, 58, 60, 62, 66, 68, 70, 7 1 , 74, 77, 80, 83, 85, 88, 90, 9 1, 93, 95, 97, 99, 100, 102, 105, 108, 110 , 112 , 115 , 117, 119 , 120, 12 1, 122, or 125 amino acid sequence from the sequence of any one of the sequences of SEQ ID NOs:8-73. It is well known in the art that BMPs are often heterogeneous with respect to the amino and/or carboxyl termini of the protein. That is, the present invention comprises a designer BMP comprising an amino acid deletion/truncation at the amino and/or carboxyl terminus comprising a deletion of at least 10 amino acid residues, preferably, 9 amino acid residues, even more preferably, 8 amino acid residues, yet more preferably, 7 amino acid residues, preferably 6 amino acid residues, even more preferably, 5 amino acid residues, preferably 4 amino acid residues, more preferably 3 amino acid residues, even more preferably 2 amino acid residues, and most preferably 1 amino acid reside from the C and or N terminus of the designer BMP. In another embodiment, the invention comprises a designer BMP protein comprising an amino acid sequence of any one of the sequences of SEQ ID NO:8-73 and further comprising a deletion/truncation from the amino and/or carboxyl termini of the protein. In another embodiment, the invention comprises a designer BMP protein derived from a BMP protein comprising an amino acid sequence of any of the sequences of SEQ ID NOs:8-73, wherein the protein comprises an amino acid deletion/truncation at the amino and/or carboxyl terminus comprising a deletion of at least 10 amino acid residues, preferably, 9 amino acid residues, even more preferably, 8 amino acid residues, yet more preferably, 7 amino acid residues, preferably 6 amino acid residues, even more preferably, 5 amino acid residues, preferably 4 amino acid residues, more preferably 3 amino acid residues, even more preferably 2 amino acid residues, and most preferably 1 amino acid reside from the C and or N terminus of the designer BMP protein amino acid sequence. Structural design of BMPs with altered receptor affinity mediated by qlycosylation The data disclosed herein demonstrate that BMP2 homodimers produced in E. coli (referred to herein as "E. coli BMP2"), which are not glycosylated, are less active than glycosylated BMP2 produced in mammalian cells, such as CHO cells (referred to herein as "CHO BMP2"). In addition, data disclosed herein further demonstrate that E. coli produced BMP6 homodimers are essentially non-functional compared with BMP6 homodimers produced in mammalian cell culture. The data disclosed herein demonstrate that there are significant variations in the crystal structure of E. coli BMP2 compared with CHO BMP2 in the type I receptor binding region. In one embodiment, the designer BMP comprises an altered conformation mediated by glycosylation thereby affecting a binding motif that, in turn, mediates altered binding to a type I receptor. This is based on the present discovery that in mammalian (e.g., CHO) cell produced wild type BMP2, D53 points towards the receptor interface while the H54 points away from the receptor. This is in contrast to E. coli-produced BMP2 where the D53 residue points away from the receptor interface and the H54 residue lines up toward the receptor, stacking against a proline reside as illustrated in Figure 3 , apparently acting as a "doorstop." In addition, the data disclosed herein demonstrate for the first time that CHO-produced BMP6, which is fully glycosylated and active, also comprises a histidine residue pointing toward the incoming receptor, i.e. , a histidine "doorstop." Without wishing to be bound by any particular theory, the data disclosed herein suggest, for the first time, that moving a "doorstop" residue away from the receptor interface, can mediate increased binding between the BMP ligand and its receptor. The data further demonstrate that the doorstop residue may be either mutated itself to remove the doorstop or other residues may be mutated to shift the position of the doorstop residue. Further, the data disclosed herein further demonstrate that other residues may be mutated to provide a "glycan tether" which then, in turn, can orient a glycan such that the tethering of the glycan will reorient the doorstop residue. Therefore, in some embodiments, a designer BMP can be produced by incorporating at least one amino acid mutation that affects the glycan tether and/or removes a histidine doorstop structure thereby providing a designer BMP with altered receptor binding. In summary, in some embodiments, the designer BMPs of the invention may comprise at least one mutation in the type I and/or type II binding domains of BMPs that confer altered type I and/or type I I receptor binding. In one embodiment, the BMP sequence is engineered to alter the receptor affinity of BMPs in order to alter and improve the receptor binding and/or osteogenic activity of the engineered or "designer" BMP. In one embodiment, this engineering involves identifying the residues involved in type I and type I I receptor binding and replacing them to create designer BMP molecules that show, among other things, higher affinity to both type I and type I I receptors than the parental BMP from which the designer is derived. In other embodiments, the designer BMPs of the invention comprise mutations that create a new arginine "glycan tether" or destroy an existing one to reshape the type I receptor binding domain. That is, the mutation to an arginine in the position two residues C-terminal from the first cysteine, equivalent to R 16 of BMP2, appears to cause the glycan chain to be "tethered" onto the BMP surface and consequently alter the conformation of the pre-helical loop region compared with the wild type BMP that lacks the mutation. In other embodiments, the designer BMP of the invention may comprise at least one mutation that alters, creates or destroys (abolishes) the "doorstop" residue that blocks type I receptor from further engagement with BMP. That is, the mutation of H54 in the designer BMP, or a corresponding equivalent residue thereof, that is oriented in such a way that it impedes or increases interaction of the designer BMP with a type I receptor. In some embodiments, the amino acid mutation affects the conformation of the designer BMP such that the mutation mediates the creation and or abolishment of an arginine "glycan tether" otherwise present in the corresponding wild type BMP. In some embodiments, the mutation mediates an altered conformation which creates or removes/abolishes a histidine doorstop conformation in the designer BMP where such doorstop conformation is either not present or active, respectively, in the corresponding wild type BMP. Therefore, the skilled artisan, once armed with the teachings provided herein, would appreciate that the presence or absence of an arginine "glycan tether" and/or a histidine "doorstop" in a TGFp superfamily member may be assessed using any method known in the art for the structural analysis of proteins, including, but not limited to, the methods exemplified herein. Once the presence of a "doorstop" residue has been identified, then at least one mutation can be introduced into the molecule to reorient the histidine away from the receptor binding interface. Alternatively, a mutation can be introduced that will create or enhance a "glycan tether" such that the inhibitory effect of the histidine "doorstop", if present, is decreased or, more preferably, eliminated. In one embodiment, where the TGFp superfamily member is BMP2, the mutation that removes the histidine doorstop is substitution of another amino acid for H54. In some embodiments, the H54 is replaced with alanine, glycine, serine, or threonine. Although the present invention discloses such "doorstop' -removing mutations for BMP2, the skilled artisan would understand, based on the knowledge in the art, how to identify corresponding mutations for other TGFp superfamily members and readily produce mutants lacking a "doorstop," i.e., removing or reorienting a residue that would otherwise interfere with receptor binding by facing or projecting into the binding interface. The effects of the mutation on protein conformation can be determined using any art-recognized method for the structural analysis of proteins such as, but not limited to, those disclosed herein. Alternatively, mutations that can remove the doorstop and increase ligand binding to the type I receptor can be identified in silico using computer modeling methods available in the art. Therefore, the present invention encompasses the design of TGFp superfamily members having improved binding with the type I receptor in that they lack a histidine "doorstop" residue that would otherwise be present in the receptor interface. The present invention further provides the skilled artisan with the understanding of how to identify mutations for other TGFp family members that would generate or destroy the arginine glycan tether. Mutations that add the arginine glycan tether to a protein lacking the tether are contemplated by the instant invention. Therefore, the present invention encompasses the design of TGFp superfamily members having improved binding with the type I receptor in that they contain an arginine glycan tether that alters the conformation of the type I receptor binding domain. In some embodiments, the removal of the histidine doorstop thereby removing the requirement of a glycan tether, provides a designer BMP that can be produced without glycosylation while maintaining biological activity. For example, designer BMPs may be produced in cells with glycosylation activity that differs from mammalian cells or is not present, such as bacterial cells, yeast cells, insect cells, or slime mold cells. In particular embodiments, the designer BMPs may be produced in E. coli and maintain biological activity. Thus, in some embodiments, the invention provides methods for designing and producing BMPs that can be produced in cells either lacking glycosylation or comprising altered glycosylation such that an altered glycan is produced which differs from that produced by a mammalian cell. That is, the present invention encompasses methods for introducing a mutation that removes a doorstop residue that would otherwise impair or inhibit receptor binding. The skilled artisan would understand once provided with the teachings of the invention that a doorstop residue that impinges upon the receptor-ligand interface may be mutated to entirely remove the residue or other mutations can be introduced such that the residue is oriented away from the interface. Such other mutations include, but are not limited to, providing a glycan tether that will alter the conformation of a glycan and thereby alter the conformation of the ligand such that the doorstop residue is orientated away from the binding interface. Nucleic Acids Encoding Designer BMPs The invention also includes nucleic acids encoding designer the BMPs described herein. Nucleic acids encoding the designer BMPs described herein can be prepared according to a wide plethora of methods known in the art. In one, nucleic acids encoding designer BMPs are prepared by total gene synthesis, or by sitedirected mutagenesis of a nucleic acid encoding wild type or modified BMPs. Methods including templatedirected ligation, recursive PCR, cassette mutagenesis, site-directed mutagenesis or other techniques that are well known in the art may be utilized (see for example Strizhov et al., Proc. Natl. Acad. Sci. USA 93: 1501 2-1 501 7 ( 1996); Prodromou and Perl, Prot. Eng. 5 : 827-829 ( 1992); Jayaraman and Puccini, Biotechniques 12 : 392-398 ( 1992); and Chalmers et al. , Biotechniques 30: 249-252 (2001 )). Thus, embodiments of the present invention can comprise nucleic acid molecules that encode the designer BMPs of the present invention. In certain embodiments, the invention provides a nucleic acid molecule that encodes for one of the amino acid sequences of SEQ ID NOs:8 to 66. In other embodiments, the nucleic acid molecule encodes a designer BMP protein that comprises an amino acid sequence at least 70%, 75% , 80%, 85%, 87%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence of SEQ ID NO: 12 . In some embodiments, the nucleic acid molecule encodes a designer BMP protein that comprises the amino acid sequence of SEQ ID NO:1 2 . In another embodiment, the nucleic acid molecule encodes the amino acid sequence of BMPE as set forth in Table 8 . In other embodiments, the nucleic acid molecule encodes a designer BMP protein that comprises an amino acid sequence at least 70%, 75% , 80%, 85%, 87%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence of SEQ ID NO: 14 . In some embodiments, the nucleic acid molecule encodes a designer BMP protein that comprises the amino acid sequence of SEQ ID NO:1 4 . In another embodiment, the nucleic acid molecule encodes the amino acid sequence of BMPG as set forth in Table 8 . In other embodiments, the nucleic acid molecule encodes a designer BMP protein that comprises an amino acid sequence at least 70%, 75% , 80%, 85%, 87%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence of SEQ ID NO:36. In some embodiments, the nucleic acid molecule encodes a designer BMP protein that comprises the amino acid sequence of SEQ ID NO:36. In another embodiment, the nucleic acid molecule encodes the amino acid sequence of BMPGE as set forth in Table 8 . In other embodiments, the nucleic acid molecule encodes a designer BMP protein that comprises an amino acid sequence at least 70%, 75% , 80%, 85%, 87%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence of SEQ ID NO:37. In some embodiments, the nucleic acid molecule encodes a designer BMP protein that comprises the amino acid sequence of SEQ ID NO:37. In another embodiment, the nucleic acid molecule encodes the amino acid sequence of BMPGER as set forth in Table 8 . Exemplary nucleotide sequences encoding designer BMPs are set forth in Table 8 , below. Table 8 shows the name of the protein encoded and the nucleotide sequence encoding that protein. In general, the mature protein coding sequence begins at nucleotide 847 of the sequences listed below. TABLE 8 NAME SEQUENCE SEQ ID NO BMP-B ATGGTGGCCGGGACCCGCTGTCTTCTAGCGTTGCTGCTTCCCCAGGTCCTCCTGGGCGGCGCGGCTGG 75 CCTCGTTCCGGAGCTGGGCCGCAGGAAGTTCGCGGCGGCGTCGTCGGGCCGCCCCTCATCCCAGCCCT CTGACGAGGTCCTGAGCGAGTTCGAGTTGCGGCTGCTCAGCATGTTCGGCCTGAAACAGAGACCCACC CCCAGCAGGGACGCCGTGGTGCCCCCCTACATGCTAGACCTGTATCGCAGGCACTCAGGTCAGCCGGG CTCACCCGCCCCAGACCACCGGTTGGAGAGGGCAGCCAGCCGAGCCAACACTGTGCGCAGCTTCCACC ATGAAGAATCTTTGGAAGAACTACCAGAAACGAGTGGGAAAACAACCCGGAGATTCTTCTTTAATTTA AGTTCTATCCCCACGGAGGAGTTTATCACCTCAGCAGAGCTTCAGGTTTTCCGAGAACAGATGCAAGA TGCTTTAGGAAACAATAGCAGTTTCCATCACCGAATTAATATTTATGAAATCATAAAACCTGCAACAG CCAACTCGAAATTCCCCGTGACCAGACTTTTGGACACCAGGTTGGTGAATCAGAATGCAAGCAGGTGG GAAAGTTTTGATGTCACCCCCGCTGTGATGCGGTGGACTGCACAGGGACACGCCAACCATGGATTCGT GGTGGAAGTGGCCCACTTGGAGGAGAAACAAGGTGTCTCCAAGAGACATGTTAGGATAAGCAGGTCTT TGCACCAAGATGAACACAGCTGGTCACAGATAAGGCCATTGCTAGTAACTTTTGGCCATGATGGAAAA GGGCATCCTCTCCACAAAAGAGAAAAACGTCAAGCCAAACACAAACAGCGGAAACGCCTTAAGTCCAG CTGTAAGAGACACCCTTTGTACGTGGACTTCAGTGACGTGGGGTGGAATGACTGGATTGTGGCTCCCC CGGGGTATCACGCCTTTTACTGCCACGGAGAATGCCCTTTTCCTCTGGCTGATCATCTGAACTCCACT AATCATGCCATTGTTCAGACGTTGGTCAACTCTGTTAACTCTAAGATTCCTAAGGCATGCTGTGTCCC GACAAAGCTAAATGCCATCTCGGTTCTTTACTTTGATGACAACTCCAATGTCATTTTAAAGAACTATC AGGACATGGTTGTGGAGGGTTGTGGGTGTCGCTGA BMP-C ATGGTGGCCGGGACCCGCTGTCTTCTAGCGTTGCTGCTTCCCCAGGTCCTCCTGGGCGGCGCGGCTGG 76 CCTCGTTCCGGAGCTGGGCCGCAGGAAGTTCGCGGCGGCGTCGTCGGGCCGCCCCTCATCCCAGCCCT CTGACGAGGTCCTGAGCGAGTTCGAGTTGCGGCTGCTCAGCATGTTCGGCCTGAAACAGAGACCCACC CCCAGCAGGGACGCCGTGGTGCCCCCCTACATGCTAGACCTGTATCGCAGGCACTCAGGTCAGCCGGG CTCACCCGCCCCAGACCACCGGTTGGAGAGGGCAGCCAGCCGAGCCAACACTGTGCGCAGCTTCCACC ATGAAGAATCTTTGGAAGAACTACCAGAAACGAGTGGGAAAACAACCCGGAGATTCTTCTTTAATTTA AGTTCTATCCCCACGGAGGAGTTTATCACCTCAGCAGAGCTTCAGGTTTTCCGAGAACAGATGCAAGA TGCTTTAGGAAACAATAGCAGTTTCCATCACCGAATTAATATTTATGAAATCATAAAACCTGCAACAG CCAACTCGAAATTCCCCGTGACCAGACTTTTGGACACCAGGTTGGTGAATCAGAATGCAAGCAGGTGG GAAAGTTTTGATGTCACCCCCGCTGTGATGCGGTGGACTGCACAGGGACACGCCAACCATGGATTCGT GGTGGAAGTGGCCCACTTGGAGGAGAAACAAGGTGTCTCCAAGAGACATGTTAGGATAAGCAGGTCTT TGCACCAAGATGAACACAGCTGGTCACAGATAAGGCCATTGCTAGTAACTTTTGGCCATGATGGAAAA GGGCATCCTCTCCACAAAAGAGAAAAACGTCAAGCCAAACACAAACAGCGGAAACGCCTTAAGTCCAG CTGTAAGAGACACCCTTTGTACGTGGACTTCAGTGACGTGGGGTGGAATGACTGGATTATTGCACCCA AGGGCTATGCTGCCAATTACTGCCACGGAGAATGCCCTTTTCCTCTGGCTGATCATCTGAACTCCACT AATCATGCCATTGTTCAGACGTTGGTCAACTCTGTTAACTCTAAGATTCCTAAGGCATGCTGTGTCCC GACAAAGCTAAATGCCATCTCGGTTCTTTACTTTGATGACAACTCCAATGTCATTTTAAAGAACTATC AGGACATGGTTGTGGAGGGTTGTGGGTGTCGCTGA BMP-D ATGGTGGCCGGGACCCGCTGTCTTCTAGCGTTGCTGCTTCCCCAGGTCCTCCTGGGCGGCGCGGCTGG 77 CCTCGTTCCGGAGCTGGGCCGCAGGAAGTTCGCGGCGGCGTCGTCGGGCCGCCCCTCATCCCAGCCCT CTGACGAGGTCCTGAGCGAGTTCGAGTTGCGGCTGCTCAGCATGTTCGGCCTGAAACAGAGACCCACC CCCAGCAGGGACGCCGTGGTGCCCCCCTACATGCTAGACCTGTATCGCAGGCACTCAGGTCAGCCGGG CTCACCCGCCCCAGACCACCGGTTGGAGAGGGCAGCCAGCCGAGCCAACACTGTGCGCAGCTTCCACC ATGAAGAATCTTTGGAAGAACTACCAGAAACGAGTGGGAAAACAACCCGGAGATTCTTCTTTAATTTA AGTTCTATCCCCACGGAGGAGTTTATCACCTCAGCAGAGCTTCAGGTTTTCCGAGAACAGATGCAAGA TGCTTTAGGAAACAATAGCAGTTTCCATCACCGAATTAATATTTATGAAATCATAAAACCTGCAACAG CCAACTCGAAATTCCCCGTGACCAGACTTTTGGACACCAGGTTGGTGAATCAGAATGCAAGCAGGTGG GAAAGTTTTGATGTCACCCCCGCTGTGATGCGGTGGACTGCACAGGGACACGCCAACCATGGATTCGT GGTGGAAGTGGCCCACTTGGAGGAGAAACAAGGTGTCTCCAAGAGACATGTTAGGATAAGCAGGTCTT TGCACCAAGATGAACACAGCTGGTCACAGATAAGGCCATTGCTAGTAACTTTTGGCCATGATGGAAAA GGGCATCCTCTCCACAAAAGAGAAAAACGTCAAGCCAAACACAAACAGCGGAAACGCCTTAAGTCCAG CTGTAAGAGACACCCTTTGTACGTGGACTTCAGTGACGTGGGGTGGAATGACTGGATTGTGGCTCCCC CGGGGTATCACGCCTTTTACTGCCACGGAGAATGCCCTTTTCCACTCAACGCACACATGAATGCAACC AACCACGCGATTGTGCAGACCTTGGTTCACCTTATGAACTCTAAGATTCCTAAGGCATGCTGTGTCCC GACAGAACTCAGTGCTATCTCGATGCTGTACCTTGACGAGAATGAAAAGGTTGTATTAAAGAACTATC AGGACATGGTTGTGGAGGGTTGTGGGTGTCGCTGA BMP-E ATGGTGGCCGGGACCCGCTGTCTTCTAGCGTTGCTGCTTCCCCAGGTCCTCCTGGGCGGCGCGGCTGG 78 CCTCGTTCCGGAGCTGGGCCGCAGGAAGTTCGCGGCGGCGTCGTCGGGCCGCCCCTCATCCCAGCCCT CTGACGAGGTCCTGAGCGAGTTCGAGTTGCGGCTGCTCAGCATGTTCGGCCTGAAACAGAGACCCACC CCCAGCAGGGACGCCGTGGTGCCCCCCTACATGCTAGACCTGTATCGCAGGCACTCAGGTCAGCCGGG CTCACCCGCCCCAGACCACCGGTTGGAGAGGGCAGCCAGCCGAGCCAACACTGTGCGCAGCTTCCACC ATGAAGAATCTTTGGAAGAACTACCAGAAACGAGTGGGAAAACAACCCGGAGATTCTTCTTTAATTTA AGTTCTATCCCCACGGAGGAGTTTATCACCTCAGCAGAGCTTCAGGTTTTCCGAGAACAGATGCAAGA TGCTTTAGGAAACAATAGCAGTTTCCATCACCGAATTAATATTTATGAAATCATAAAACCTGCAACAG CCAACTCGAAATTCCCCGTGACCAGACTTTTGGACACCAGGTTGGTGAATCAGAATGCAAGCAGGTGG GAAAGTTTTGATGTCACCCCCGCTGTGATGCGGTGGACTGCACAGGGACACGCCAACCATGGATTCGT GGTGGAAGTGGCCCACTTGGAGGAGAAACAAGGTGTCTCCAAGAGACATGTTAGGATAAGCAGGTCTT TGCACCAAGATGAACACAGCTGGTCACAGATAAGGCCATTGCTAGTAACTTTTGGCCATGATGGAAAA GGGCATCCTCTCCACAAAAGAGAAAAACGTCAAGCCAAACACAAACAGCGGAAACGCCTTAAGTCCAG CTGTAAGAGACACCCTTTGTACGTGGACTTCAGTGACGTGGGGTGGAATGACTGGATTGTGGCTCCCC NAME SEQUENCE SEQ ID NO CGGGGTATCACGCCTTTTACTGCGATGGAGAATGCTCCTTCCCACTCAACGCACACATGAATGCAACC AACCACGCGATTGTGCAGACCTTGGTTCACCTTATGAACCCCGAGTATGTCCCCAAACCGTGCTGTGC GCCGACAGAACTCAGTGCTATCTCGATGCTGTACCTTGACGAGAATGAAAAGGTTGTATTAAAGAACT ATCAGGACATGGTTGTGGAGGGTTGTGGGTGTCGCTGA BMP-F ATGGTGGCCGGGACCCGCTGTCTTCTAGCGTTGCTGCTTCCCCAGGTCCTCCTGGGCGGCGCGGCTGG 79

CLAIMS 1. A designer BMP protein comprising at least one mutation in at least one type I or type I I receptor binding domain, wherein the mutation confers altered binding to the type I or type I I BMP receptor compared with the binding to the type I or type I I receptor by a corresponding wild type BMP. 2 . The protein of claim 1, wherein the protein is selected from the group consisting of BMP2, BMP4, BMP5, BMP6, BMP7, BMP8 and BMP9. 3 . The protein of claim 1, comprising at least one mutation within: a . the type I I binding domain A; b. the type II binding domain B; c . the type I binding domain; and d . any combination of the above. 4 . A designer osteogenic protein comprising an amino acid sequence comprising at least one mutation in at least one type I or type I I receptor binding domain, wherein the mutation confers altered binding to the type I or type I I BMP receptor compared with the binding to the type I or type I I receptor by wild type BMP2. 5 . The protein of claim 4 , wherein the mutation is selected from the group consisting of: a . a mutation within the type I I binding domain A wherein said mutation is at least one mutation selected from the group consisting of a mutation at V33, P36, H39, and F41 with respect to the sequence of SEQ ID NO:1 ; b. a mutation within the type I I binding domain A wherein said mutation is at least one mutation selected from the group consisting of V33I, P36K, P36R, H39A, and F41 N with respect to SEQ ID NO:1 ; c . a mutation within the type I I binding domain B wherein said mutation is at least one mutation selected from the group consisting of a mutation at E83, S85, M89, L92, E94, E96, K97, and V99 with respect to the sequence of SEQ ID NO: 1; d . a mutation within the type I I binding domain B wherein said mutation is at least one mutation selected from the group consisting of E83K, S85N, M89V, L92F, E94D, E96S, K97N, and V99I with respect to of SEQ ID NO:1 ; e. a mutation within the type I binding domain wherein said mutation is at least one mutation selected from the group consisting of a mutation at H44, P48, A52, D53, L55, S57, N68, S69, V70, an insertion of a single amino acid after N71 , S72, K73, I74, A77, and V80 with respect to the sequence of SEQ ID NO:1 ; and f . a mutation within the type I binding domain wherein said mutation is at least one mutation selected from the group consisting of H44D, P48S, A52N, D53A, L55M, S57A, N68H, S69L, V70M, insertion of P after N71 , S72E, K73Y, I74V, A77P, and V80A with respect to the sequence of SEQ ID NO:1 . 6. The protein of claim 4 , wherein said protein comprises mutations selected from the group consisting of: a . a mutation at each of amino acids H44, P48, A52, D53, L55, S57, N68, S69, V70, insertion of a single amino acid after N71 , S72, K73, I74, A77, and V80 with respect to the sequence of SEQ ID NO:1 ; b. the protein of (a) wherein the mutations are H44D, P48S, A52N, D53A, L55M, S57A, N68H, S69L, V70M, insertion of a P after N71 , S72E, K73Y, I74V, A77P, and V80A; c . a mutation at each of amino acids V33, P36, H39, S85, M89, L92, E94, E96, K97, and V99 with respect to the sequence of SEQ ID NO:1 ; d . the protein of (c) wherein the mutations are V33I, P36K, H39A, S85N, M89, L92F, E94D, E96S, K97N , and V99I; e. a mutation at each of amino acids V33, P36, H39, H44, P48, A52, D53, L55, S57, N68, S69, V70, insertion of a single amino acid after N71 , S72, K73, I74, A77, and V80, S85, M89, L92, E94, E96, K97, and V99 with respect to the sequence of SEQ ID NO:1 ; and f . the protein of (e) wherein the mutations are V33I, P36K, H39A, H44D, P48S, A52N, D53A, L55M, S57A, N68H , S69L, V70M, insertion of a P after N71 , S72E, K73Y, I74V, A77P, and V80A, S85N, M89, L92F, E94D, E96S, K97N , and V99I; and g . the protein of (e) wherein the mutations are V33I , P36R, H39A, H44D, P48S, A52N, D53A, L55M, S57A, N68H , S69L, V70M, insertion of a P after N71 , S72E, K73Y, I74V, A77P, and V80A, S85N, M89, L92F, E94D, E96S, K97N , and V99I. 7. The protein of claim 1, wherein the protein binds the ALK2 receptor with a K not greater than about 2 nM, the protein binds the ALK3 receptor with a K not greater than about 2 nM, the protein binds the ALK6 receptor with a K not greater than about 1 nM, the protein binds the ActRMA receptor with a K not greater than about 2 nM, the protein binds the ActRMB receptor with a K not greater than about 0.5 nM, and protein binds the BMPRMA receptor with a K not greater than about 3.5 nM. 8 . The protein of claim 1, further comprising 1, 2 , 3 , 4 , 5, 6, 7, 8 , 9 , or 10 amino acid mutations not located within the type I or the type I I binding regions. 9 . A designer osteogenic protein selected from a protein comprising the amino acid sequence of any one of SEQ ID NOs:8-73. 10 . A designer osteogenic protein comprising the amino acid sequence of SEQ ID NO:1 2 . 11. A designer osteogenic protein comprising the amino acid sequence of SEQ ID NO:1 4 . 12 . A designer osteogenic protein comprising the amino acid sequence of SEQ ID NO:36. 13. A designer osteogenic protein comprising the amino acid sequence of SEQ ID NO:37. 14 . A method of producing the protein of claim 1, the method comprising introducing a nucleic acid encoding the protein into a host cell, culturing the cell under conditions where the protein is produced, and purifying the protein. 15. The method of claim 14 , wherein said nucleic acid comprises a sequence selected from the group consisting of the nucleic acid sequence of any one of SEQ ID NOs:74-1 39. 16. A designer BMP6 protein comprising an amino acid sequence comprising at least one mutation in at least one type I or type I I receptor binding domain, wherein the mutation confers altered binding to the type I or type I I BMP receptor compared with the binding to the type I or type I I receptor by wild type BMP6. 17. The protein of claim 16, wherein the mutation is selected from the group consisting of: a . a mutation within the type I I binding domain A wherein said mutation is at least one mutation selected from the group consisting of a mutation at I57, K60, G61 , A63, N65, Y66, and D68 with respect to the sequence of SEQ ID NO:4; b. a mutation within the type I I binding domain B wherein said mutation is at least one mutation selected from the group consisting of K 108, N 110 , A 111, V 114 , F 117, D 119 , N 120, S 12 1, N 122, V 123, and 11 24 with respect to the sequence of SEQ ID NO:4; c . a mutation within the type I binding domain wherein said mutation is at least one mutation selected from the group consisting of a mutation at S72, N76, A77, H78, M79, N80, A81 , N83, V87, T89, H92, L93, M94, N95, P96, E97, Y98, V99, and P 100 with respect to the sequence of SEQ ID NO:4; d. a mutation at each of amino acid residues I57, K60, G61 , A63, N65, Y66, and D68 with respect to the sequence of SEQ ID NO:4; e. a mutation at each of amino acid residues K 108, N 110 , A 111, V 114 , F 1 17, D 119 , N 120, S 12 1, N122, V 123, and 1124 with respect to the amino acid sequence of SEQ ID NO:4; and f . a mutation at each of amino acid residues S72, N76, A77, H78, M79, N80, A81 , N83, V87, T89, H92, L93, M94, N95, P96, E97, Y98, V99, or P 100 with respect to the amino acid sequence of SEQ ID NO:4. 18 . The protein of claim 16, further comprising 1, 2 , 3, 4 , 5, 6, 7 , 8 , 9 , or 10 amino acid mutations not located within the type I or the type I I binding domains. 19 . An isolated nucleic acid molecule comprising a nucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ ID NOs:8 to 73. 20. The nucleic acid of claim 19 , said nucleic acid encoding a protein comprising an amino acid sequence selected from the group consisting of the sequence of SEQ ID NO:1 2 , SEQ ID NO:1 4 , SEQ ID NO:36 and SEQ ID NO:37. 2 1. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:74 to 139. 22. The nucleic acid of claim 2 1, said nucleic acid comprising a nucleotide sequence selected from the group consisting of the sequence of SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:1 02, and SEQ ID NO: 103. 23. A method of producing the protein of claim 16 , the method comprising introducing a nucleic acid encoding said protein into a host cell, culturing said cell under conditions where said protein is produced , and purifying said protein. 24. A method of treating a bone disease associated with bone loss in a patient in need thereof, the method comprising administering an effective amount of a designer osteogenic protein of claim 1 to said patient, thereby treating bone disease in said patient. 25. A method of treating fibrosis in a patient in need thereof, the method comprising administering an effective amount of a designer osteogenic protein of claim 1 to said patient, thereby treating fibrosis. 26. A method of inducing bone formation in a tissue, said method comprising contacting said tissue with a designer osteogenic protein of claim 1, thereby inducing bone formation in said tissue.

Documents

Sign in to open
Orders
Section Granted u/s 15Controller: Rajiv Kumar Singh 28 Jan 2020
Section Granted u/s 15Controller: Rajiv Kumar Singh 28 Jan 2020
Application documents
1 841-DELNP-2013.pdf 05 Feb 2013
2 841-delnp-2013-Correspondence Others-(21-02-2013).pdf 21 Feb 2013
3 841-delnp-2013-Form-3-(29-07-2013).pdf 29 Jul 2013
4 841-delnp-2013-Correspondence Others-(29-07-2013).pdf 29 Jul 2013
5 841-delnp-2013-Form-5.pdf 20 Aug 2013
6 841-delnp-2013-Form-3.pdf 20 Aug 2013
7 841-delnp-2013-Form-2.pdf 20 Aug 2013
8 841-delnp-2013-Form-18.pdf 20 Aug 2013
9 841-delnp-2013-Form-1.pdf 20 Aug 2013
10 841-delnp-2013-Correspondence-others.pdf 20 Aug 2013
11 841-delnp-2013-Claims.pdf 20 Aug 2013
12 841-delnp-2013-GPA-(12-09-2013).pdf 12 Sep 2013
13 841-delnp-2013-Correspondence Others-(12-09-2013).pdf 12 Sep 2013
14 841-DELNP-2013-FER.pdf 08 Sep 2017
15 841-DELNP-2013-Information under section 8(2) (MANDATORY) [02-11-2017(online)]_10.pdf 02 Nov 2017
16 841-DELNP-2013-Information under section 8(2) (MANDATORY) [02-11-2017(online)].pdf 02 Nov 2017
17 841-DELNP-2013-FORM 3 [02-11-2017(online)].pdf 02 Nov 2017
18 841-DELNP-2013-RELEVANT DOCUMENTS [06-03-2018(online)].pdf 06 Mar 2018
19 841-DELNP-2013-MARKED COPIES OF AMENDEMENTS [06-03-2018(online)].pdf 06 Mar 2018
20 841-DELNP-2013-Annexure [06-03-2018(online)].pdf 06 Mar 2018
21 841-DELNP-2013-AMMENDED DOCUMENTS [06-03-2018(online)].pdf 06 Mar 2018
22 841-DELNP-2013-Amendment Of Application Before Grant - Form 13 [06-03-2018(online)].pdf 06 Mar 2018
23 841-DELNP-2013-SEQUENCE LISTING [07-03-2018(online)].jpg 07 Mar 2018
24 841-DELNP-2013-OTHERS [07-03-2018(online)].pdf 07 Mar 2018
25 841-DELNP-2013-FER_SER_REPLY [07-03-2018(online)].pdf 07 Mar 2018
26 841-DELNP-2013-DRAWING [07-03-2018(online)].pdf 07 Mar 2018
27 841-DELNP-2013-COMPLETE SPECIFICATION [07-03-2018(online)].pdf 07 Mar 2018
28 841-DELNP-2013-CLAIMS [07-03-2018(online)].pdf 07 Mar 2018
29 841-DELNP-2013-ABSTRACT [07-03-2018(online)].pdf 07 Mar 2018
30 841-DELNP-2013-FORM 3 [11-10-2018(online)].pdf 11 Oct 2018
31 841-DELNP-2013-FORM 3 [28-01-2019(online)].pdf 28 Jan 2019
32 841-DELNP-2013-REQUEST FOR ADJOURNMENT OF HEARING UNDER RULE 129A [25-09-2019(online)].pdf 25 Sep 2019
33 841-DELNP-2013-HearingNoticeLetter30-09-2019.pdf 30 Sep 2019
34 841-DELNP-2013-Correspondence to notify the Controller (Mandatory) [24-10-2019(online)].pdf 24 Oct 2019
35 841-DELNP-2013-ExtendedHearingNoticeLetter_25-10-2019.pdf 25 Oct 2019
36 841-DELNP-2013-PETITION UNDER RULE 137 [06-11-2019(online)].pdf 06 Nov 2019
37 841-DELNP-2013-Written submissions and relevant documents (MANDATORY) [07-11-2019(online)].pdf 07 Nov 2019
38 841-DELNP-2013-PatentCertificate28-01-2020.pdf 28 Jan 2020
39 841-DELNP-2013-IntimationOfGrant28-01-2020.pdf 28 Jan 2020
40 841-DELNP-2013-RELEVANT DOCUMENTS [04-09-2021(online)].pdf 04 Sep 2021
41 841-DELNP-2013-RELEVANT DOCUMENTS [27-09-2021(online)].pdf 27 Sep 2021
42 841-DELNP-2013-RELEVANT DOCUMENTS [22-09-2022(online)].pdf 22 Sep 2022
43 841-DELNP-2013-RELEVANT DOCUMENTS [10-09-2023(online)].pdf 10 Sep 2023
Search strategy
1SearchStartegy_841-DELNP-2013_30-08-2017.pdf

ERegister / renewals

Inforce
3rd Renewed 24 Apr 2020 Period 17 Aug 2013 – 17 Aug 2014 · CBR 13688 · Certificate 27406 ₹4,000
4th Renewed 24 Apr 2020 Period 17 Aug 2014 – 17 Aug 2015 · CBR 13688 · Certificate 27407 ₹4,000
5th Renewed 24 Apr 2020 Period 17 Aug 2015 – 17 Aug 2016 · CBR 13688 · Certificate 27408 ₹4,000
6th Renewed 24 Apr 2020 Period 17 Aug 2016 – 17 Aug 2017 · CBR 13688 · Certificate 27409 ₹4,000
7th Renewed 24 Apr 2020 Period 17 Aug 2017 – 17 Aug 2018 · CBR 13688 · Certificate 27410 ₹12,000
8th Renewed 24 Apr 2020 Period 17 Aug 2018 – 17 Aug 2019 · CBR 13688 · Certificate 27411 ₹12,000
9th Renewed 24 Apr 2020 Period 17 Aug 2019 – 17 Aug 2020 · CBR 13688 · Certificate 27412 ₹12,000
10th Renewed 10 Aug 2020 Period 17 Aug 2020 – 17 Aug 2021 · CBR 26115 · Certificate 47850 ₹12,000
11th Renewed 11 Aug 2021 Period 17 Aug 2021 – 17 Aug 2022 · CBR 28131 · Certificate 54816 ₹24,000
12th Renewed 11 Aug 2022 Period 17 Aug 2022 – 17 Aug 2023 · CBR 30434 · Certificate 57895 ₹24,000
13th Renewed 09 Aug 2023 Period 17 Aug 2023 – 17 Aug 2024 · CBR 35843 · Certificate 78370 ₹24,000
14th Renewed 08 Aug 2024 Period 17 Aug 2024 – 17 Aug 2025 · CBR 51133 · Certificate 175765 ₹24,000
15th Renewed 06 Aug 2025 Period 17 Aug 2025 – 17 Aug 2026 · CBR 40901 · Certificate 63311 ₹24,000